ABCA1 p.Trp590Ser
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 21567408
[PubMed]
Nakagawa H et al: "Ubiquitin-mediated proteasomal degradation of ABC transporters: a new aspect of genetic polymorphisms and clinical impacts."
No.
Sentence
Comment
155
Effect of Mutations and Nonsynonymous SNPs on Protein Trafficking, Maturation, or ERAD of ABC Transporters Protein AA Mutation/SNP Effect on Protein Reference ABCA1 W590S Mutation Functional defect 115 R587W Mutation Impaired glycol processing 115 Q597R Mutation Impaired glycol processing, ERAD 115,116 Y1532C Mutation Altered protein trafficking 117 R1925Q Mutation Altered protein trafficking 118 ABCA3 R43L Mutation Altered protein trafficking 119 L101P Mutation Altered protein trafficking 119 R280C Mutation Altered protein trafficking 119 ABCA4 L541P Mutation Mislocalization 120 R602W Mutation Mislocalization 120 A1038V Mutation Mislocalization 120 C1490Y Mutation Mislocalization 120 ABCB1a G268V Mutation ERAD 121 G341C Mutation ERAD 121 I1196S Mutation Reduced glycosylation 122 ABCB4 I541F Mutation Accumulation in ER 123 ABCB11a E135K Mutation Reduced level of mature protein 124 L198P Mutation Reduced level of mature protein 124 E297G Mutation Reduced level of mature protein 124 L413W Mutation Reduced level of mature protein 124 R432T Mutation Reduced level of mature protein 124 D482G Mutation Immature protein in ER 124,125 N490D Mutation Reduced level of mature protein 124 A570T Mutation Reduced level of mature protein 124 T655I Mutation Reduced level of mature protein 124 Y818F SNP Moderate reduction of protein 124 G982R Mutation Retention in ER 125 R1153C Mutation ERAD 125 R1286Q Mutation Retention in ER 125 ABCC2a R768W Mutation Impaired protein trafficking 126 I1173F Mutation Impaired protein maturation 127 R1392 Mutation Impaired protein maturation 128 M1393 Mutation Impaired protein maturation 129 ABCC4a E757K SNP Altered protein trafficking 23 ABCC7 F508 Mutation Misfolding, ERAD 36-39,130 G85E Mutation Impaired protein maturation 130-132 G91R Mutation Impaired protein maturation 130-132 N1303K Mutation Impaired protein maturation 130-132 ABCC8 WT Wild type Ubiquitin-proteasome degradation 133 A116P Mutation Ubiquitin-proteasome degradation 133 V187D Mutation Ubiquitin-proteasome degradation 133 F1388 Mutation Impaired protein trafficking 134 L1544P Mutation Impaired protein trafficking 135,136 ABCC11a G180R SNP Ubiquitin-proteasome degradation 50 27 Mutation Ubiquitin-proteasome degradation 50 ABCG2a V12M SNP Altered protein localization 96 Q141K SNP Ubiquitin-proteasome degradation 102 F208S SNP Ubiquitin-proteasome degradation 78,99 S441N SNP Ubiquitin-proteasome degradation 78,99 Mutations of ABCA1, ABCA3, ABCA4, ABCB4, ABCB11, ABCC2, ABCC7 (CFTR), and ABCC8 are associated with Tangier disease, fatal surfactant deficiency, Stargardt disease, progressive familial intrahepatic cholestasis type 3 (PFIC-3), progressive familial intrahepatic cholestasis type 2 (PFIC-2), Dubin-Johnson syndrome, cystic fibrosis, and familial hyperinsulinism, respectively.
X
ABCA1 p.Trp590Ser 21567408:155:165
status: NEW
PMID: 21389634
[PubMed]
Ueda K et al: "ABC proteins protect the human body and maintain optimal health."
No.
Sentence
Comment
96
The Tangier mutation W590S, with one amino acid substitution in the first ECD, impairs HDL formation.64,66) Nagao analyzed the function of this Tangier mutant in detail, and found that it greatly decreases NaTC-dependent cholesterol and PC efflux.87) The kinetics of apoA-I binding to cells expressing ABCA1- W590S were similar to those for cells expressing wild-type ABCA1, consistently with a previous report that the W590S mutation does not impair apoA-I binding,64,65,88,89) but the W590S mutation delayed the dissociation of apoA-I from ABCA1.87) Based on these results, we proposed a four-step model for ABCA1-mediated HDL formation (Fig. 4),90) at the apoA-I binding step, ATP binding and/or hydrolysis causes conformational changes within the ECDs of ABCA1, to which apoA-I directly binds; at the translocation step, lipid translocation by ABCA1, which is apoA-I-independent occurs; at the loading step, lipid loading of apoA-I bound to ABCA1 occurs; and at the dissociation step, dissociation of lipid-loaded apoA-I from ABCA1 occurs.
X
ABCA1 p.Trp590Ser 21389634:96:21
status: NEWX
ABCA1 p.Trp590Ser 21389634:96:309
status: NEWX
ABCA1 p.Trp590Ser 21389634:96:420
status: NEWX
ABCA1 p.Trp590Ser 21389634:96:487
status: NEW98 ApoA-I undergoes a conformational transition in response to lipids,91) and lipidated apoA-I does not interact with ABCA1.82,92) Because the W590S mutation impairs the translocation step, apoA-I can remain in lipid-free conformation, which has high affinity for ABCA1.
X
ABCA1 p.Trp590Ser 21389634:98:140
status: NEW
PMID: 22607224
[PubMed]
Ma CI et al: "Tweaking the cholesterol efflux capacity of reconstituted HDL."
No.
Sentence
Comment
6
Efflux to PC-containing rHDL was stimulated by transfection of a nonfunctional ABCA1 mutant (W590S), suggesting that binding to ABCA1 represents a competing interaction.
X
ABCA1 p.Trp590Ser 22607224:6:93
status: NEW17 L`efflux de rHDL contenant de la PC était stimulé par la transfection d`un mutant d`ABCA1 non fonctionnel (W590S), suggérant que la liaison à ABCA1 représente une interaction compétitive.
X
ABCA1 p.Trp590Ser 22607224:17:117
status: NEW67 BHK cells overexpressing ABCG1, ABCA1, and a nonfunctional mutant, W590S ABCA1, were generated using mifepristone-inducible GeneSwitch system as previously described (Vaughan and Oram 2005, 2006).
X
ABCA1 p.Trp590Ser 22607224:67:67
status: NEW113 Thus, as a negative control, we included BHK cells that inducibly express a nonfunctional mutant ABCA1 (W590S).
X
ABCA1 p.Trp590Ser 22607224:113:104
status: NEW140 Efflux assays were performed with the four rHDL (5 mg panel A; 10 mg panel B) in the different cholesterol loaded BHK cells: BHK cells with no expressed protein (WT); BHK cells expressing ABCA1 (ABCA1); BHK cells expressing a dominant negative mutant of ABCA1 (ABCA1 W590S); and BHK cells expressing ABCG1 (ABCG1).
X
ABCA1 p.Trp590Ser 22607224:140:267
status: NEW146 Secondly, for WT-PC rHDL, a demonstrable increase in binding to ABCA1 and ABCG1-expressing cells was observed, with no increase in binding to cells expressing the nonfunctional W590S ABCA1, compared with control BHK cells.
X
ABCA1 p.Trp590Ser 22607224:146:177
status: NEW149 Thirdly, for WT-SM rHDL, we observed a moderate decrease in binding to ABCA1-expressing cells, a moderate increase in binding to ABCA1 W590S-expressing cells, and a sizeable and significant increase in binding to ABCG1-expressing cells.
X
ABCA1 p.Trp590Ser 22607224:149:135
status: NEW170 Binding assays were performed with the four radiolabeled rHDL (10 mg apoA-I protein) on BHK cells with no expressed protein (WT), BHK cells expressing ABCA1 (ABCA1), BHK cells expressing a nonfunctional mutant ABCA1 (ABCA1 W590S), and BHK cells expressing ABCG1 (ABCG1).
X
ABCA1 p.Trp590Ser 22607224:170:223
status: NEW198 However, rHDL with SM does not interact with ABCA1 (compare the efflux and binding for each rHDL with ABCA1 and the nonfunctional ABCA1 W590S).
X
ABCA1 p.Trp590Ser 22607224:198:136
status: NEW
PMID: 22064972
[PubMed]
Zhao GJ et al: "The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids."
No.
Sentence
Comment
43
ApoA-I failed to increase ABCA1-W590S levels in these studies, suggesting that apoA-I binding was not sufficient for ABCA1 stabilization (36).
X
ABCA1 p.Trp590Ser 22064972:43:32
status: NEW45 Another interpretation is that apoA-I fails to bind the W590S mutant in the correct orientation, and therefore the appropriate conformational change of ABCA1 required to decrease calpain proteolysis does not occur.
X
ABCA1 p.Trp590Ser 22064972:45:56
status: NEW194 This appears to be a necessary, but not sufficient, step for lipid efflux (88), because, in the case of the ABCA1 mutant (Trp590Ser) that is associated with Tangier disease, an apoA-I/ABCA1 complex also is formed, but the apoA-I is not lipidated (15).
X
ABCA1 p.Trp590Ser 22064972:194:122
status: NEW
No.
Sentence
Comment
58
However, the analysis of naturally-occurring ABCA1 mutations indicates that the solubilization and release of apoA-I with lipids may not be a passive process, as the missense mutation W590S, which is still able to bind and release apoA-I back into the media, has a low capacity to transfer lipids to the released apoA-I [47,48,52].
X
ABCA1 p.Trp590Ser 21920460:58:184
status: NEW
PMID: 21554545
[PubMed]
Nagao K et al: "Function and regulation of ABCA1--membrane meso-domain organization and reorganization."
No.
Sentence
Comment
82
The third group is the 'lipid translocation defect mutant`, represented by the W590S mutation in the first ECD of ABCA1 (Table 2).
X
ABCA1 p.Trp590Ser 21554545:82:79
status: NEW83 The subcellular distribution of W590S is indistinguishable from that of wild-type ABCA1.
X
ABCA1 p.Trp590Ser 21554545:83:33
status: NEW84 Furthermore, W590S mutation does not affect apoA-I binding [9,10,49,50]; however, W590S mutation reduced phosphatidylserine (PS) flopping activity of ABCA1, detected with the annexin V binding assay [49], and impaired sodium taurocholate-dependent cholesterol and phospholipid efflux by ABCA1 [51].
X
ABCA1 p.Trp590Ser 21554545:84:13
status: NEWX
ABCA1 p.Trp590Ser 21554545:84:82
status: NEW85 These results suggest that W590S mutation affects the lipid translocation activity of ABCA1 and that the two activities of ABCA1 (apoA-I binding and lipid translocation) can be separable (Fig. 3A).
X
ABCA1 p.Trp590Ser 21554545:85:27
status: NEW86 Additionally, W590S mutation retarded the dissociation of apoA-I from ABCA1 [51].
X
ABCA1 p.Trp590Ser 21554545:86:14
status: NEW
No.
Sentence
Comment
1587
The exception to this behavior is the activity of the ABCA1 (W590S) missense mutant that is still able to bind and release apoA-I back into the media but fails to transfer lipid to the released apoA-I [24,25,28,29].
X
ABCA1 p.Trp590Ser 20138281:1587:61
status: NEW
PMID: 19344898
[PubMed]
Maekawa M et al: "A novel missense mutation of ABCA1 in transmembrane alpha-helix in a Japanese patient with Tangier disease."
No.
Sentence
Comment
152
The loss of lipid efflux without impaired apo A-I binding was also observed in A255T, W590S, and T929I mutations [18].
X
ABCA1 p.Trp590Ser 19344898:152:86
status: NEW153 Surface binding of apo A-I was intact in W590S mutant-transfected HeLa and HEK293 cells [18,26], and direct binding of apo A-I was enhanced in the W590S mutant compared with wild-type ABCA1 in chemical cross-linking studies [27,28].
X
ABCA1 p.Trp590Ser 19344898:153:41
status: NEWX
ABCA1 p.Trp590Ser 19344898:153:147
status: NEW155 Rigot et al. [26] reported that the reduction of plasma membrane flipping might underlie the loss of lipid efflux in the W590S mutant.
X
ABCA1 p.Trp590Ser 19344898:155:121
status: NEW
PMID: 19202195
[PubMed]
Nagao K et al: "Sodium taurocholate-dependent lipid efflux by ABCA1: effects of W590S mutation on lipid translocation and apolipoprotein A-I dissociation."
No.
Sentence
Comment
0
Sodium taurocholate-dependent lipid efflux by ABCA1: effects of W590S mutation on lipid translocation and apolipoprotein A-I dissociation Kohjiro Nagao,* Yu Zhao,* Kei Takahashi,* Yasuhisa Kimura,* and Kazumitsu Ueda1,*,† * Laboratory of Cellular Biochemistry,* Division of Applied Life Sciences, Kyoto University Graduate School of Agriculture, Kyoto 606-8502, Japan; and Institute for Integrated Cell-Material Sciences,† Kyoto University, Kyoto 606-8502, Japan Abstract ABCA1 plays a major role in HDL metabolism.
X
ABCA1 p.Trp590Ser 19202195:0:64
status: NEW6 The Tangier disease mutation W590S, which resides in the extracellular domain and impairs apoA-I-dependent lipid efflux, greatly decreased NaTC-dependent cholesterol and phospholipid efflux.
X
ABCA1 p.Trp590Ser 19202195:6:13
status: NEWX
ABCA1 p.Trp590Ser 19202195:6:29
status: NEW7 However, the W590S mutation did not impair apoA-I binding and, conversely, retarded the dissociation of apoA-I from ABCA1.
X
ABCA1 p.Trp590Ser 19202195:7:13
status: NEWX
ABCA1 p.Trp590Ser 19202195:7:31
status: NEW8 These results suggest that the W590S mutation impairs ATP-dependent lipid translocation and that lipid translocation or possibly lipid loading, facilitates apoA-I dissociation from ABCA1.
X
ABCA1 p.Trp590Ser 19202195:8:31
status: NEWX
ABCA1 p.Trp590Ser 19202195:8:247
status: NEW9 NaTC is a good tool for analyzing ABCA1-mediated lipid efflux and allows dissection of the steps of HDL formation by ABCA1.- Nagao, K., Y. Zhao, K. Takahashi, Y. Kimura, and K. Ueda. Sodium taurocholate-dependent lipid efflux by ABCA1: effects of W590S mutation on lipid translocation and apolipoprotein A-I dissociation.
X
ABCA1 p.Trp590Ser 19202195:9:247
status: NEW45 Cell culture Human embryonic kidney (HEK293) cells and WI-38 fibroblasts were grown in a humidified incubator (5% CO2) at 37°C in DMEM supplemented with 10% heat-inactivated FBS. Plasmids The expression vectors for wild-type ABCA1, ABCA1-W590S, and ABCA1-K939M,K1952M (MM), fused to GFP at their C termini, were generated as described previously (3, 18).
X
ABCA1 p.Trp590Ser 19202195:45:243
status: NEW101 The W590S Tangier mutation impairs NaTC-dependent lipid efflux but not apoA-I binding It has been reported that ABCA1 carrying the Tangier disease mutation W590S in the first extra cellular domain is correctly targeted to the plasma membrane and interacts with apoA-I but fails to mediate normal apoA-I-dependent lipid efflux (3, 26-28).
X
ABCA1 p.Trp590Ser 19202195:101:4
status: NEWX
ABCA1 p.Trp590Ser 19202195:101:156
status: NEW102 We compared NaTC-dependent lipid efflux from HEK293 cells stably expressing wild-type or ABCA1-W590S fused to GFP at the C terminus.
X
ABCA1 p.Trp590Ser 19202195:102:95
status: NEW103 Western blotting (Fig. 4A) and fluorescence microscopy (see supplementary Fig. II) suggested that the expression and surface localization of the wild type and ABCA1-W590S were similar.
X
ABCA1 p.Trp590Ser 19202195:103:165
status: NEW104 Both NaTC-dependent and apoA-I-dependent cholesterol and phospholipid efflux were greatly decreased by the W590S mutation (Fig. 4B, C).
X
ABCA1 p.Trp590Ser 19202195:104:107
status: NEW105 As previously reported, apoA-I bound to the cell surface expressing ABCA1-W590S as efficiently as to that expressing wild-type ABCA1 (see supplementary Fig. II).
X
ABCA1 p.Trp590Ser 19202195:105:74
status: NEW119 1168 Journal of Lipid Research Volume 50, 2009 atHealthScienceLibraryCB#7585,onSeptember24,2012www.jlr.orgDownloadedfrom 0.DC1.html are mediated by ABCA1 in an ATP-dependent manner, are in fact separable and that the W590S mutation impairs only the latter step.
X
ABCA1 p.Trp590Ser 19202195:119:4
status: NEWX
ABCA1 p.Trp590Ser 19202195:119:218
status: NEW124 The W590S mutation also impaired cholesterol secretion at 27°C.
X
ABCA1 p.Trp590Ser 19202195:124:4
status: NEWX
ABCA1 p.Trp590Ser 19202195:124:68
status: NEW127 The kinetics of apoA-I binding to cells expressing ABCA1-W590S was quite similar to that to cells expressing wild-type ABCA1.
X
ABCA1 p.Trp590Ser 19202195:127:57
status: NEW129 In contrast, ,40% of apoA-I dissociated from cells expressing ABCA1-W590S in 2 min, and ?60% of apoA-I dissociated in 4 min.
X
ABCA1 p.Trp590Ser 19202195:129:68
status: NEW130 These results suggest that the W590S mutation retards apoA-I dissociation from cells.
X
ABCA1 p.Trp590Ser 19202195:130:31
status: NEW138 The W590S mutation impairs NaTC-dependent lipid efflux by ABCA1.
X
ABCA1 p.Trp590Ser 19202195:138:4
status: NEW141 The efflux of cellular free cholesterol (B) and choline phospholipids (C) was analyzed. HEK/ABCA1-GFP cells and HEK/ ABCA1-W590S-GFP cells were incubated for 24 h in DMEM containing 0.02% BSA (open bars), 0.02% BSA and 1 mM NaTC (filled bars), or 0.02% BSA and 5 mg/ml apoA-I (hatched bars).
X
ABCA1 p.Trp590Ser 19202195:141:123
status: NEW144 HEK/ABCA1-GFP, HEK/ABCA1-MM-GFP, or HEK/ABCA1-W590S-GFP cells were incubated with 5 mg/ml Alexa546-labeled apoA-I for the indicated times at 27°C.
X
ABCA1 p.Trp590Ser 19202195:144:46
status: NEW154 There may be other proteins (32, 33) in WI-38 cells that mediate cholesterol efflux in the presence of apoA-I. Alternatively, binding of significant amounts of apoA-I on the cell surface may cause spontaneous cholesterol loading on apoA-I. Indeed, greater cholesterol efflux was observed in the presence of apoA-I from cells expressing ABCA1-W590S, which allows apoA-I binding, than in the presence of NaTC, and this effect was strongly suppressed at 27°C (Fig. 4; see supplementary Fig. VI).
X
ABCA1 p.Trp590Ser 19202195:154:342
status: NEW161 The Tangier mutation W590S, which impairs apoA-I-dependent lipid efflux, greatly decreased NaTC-dependent cholesterol and phospholipid efflux.
X
ABCA1 p.Trp590Ser 19202195:161:21
status: NEW162 It has been reported that ABCA1-W590S interacts in a normal manner with ATP (3).
X
ABCA1 p.Trp590Ser 19202195:162:32
status: NEW163 The W590S mutation may abolish the coupling of ATP-induced conformational changes of ABCA1 with lipid translocation.
X
ABCA1 p.Trp590Ser 19202195:163:4
status: NEW164 The kinetics of apoA-I binding to cells expressing ABCA1-W590S were similar to those of binding to cells expressing wild-type ABCA1, consistent with a previous report showing that the W590S mutation does not impair apoA-I binding (8, 26-28).
X
ABCA1 p.Trp590Ser 19202195:164:57
status: NEWX
ABCA1 p.Trp590Ser 19202195:164:184
status: NEW165 Thus, the W590S mutation would not affect the conformational changes of ABCA1 Fig. 7.
X
ABCA1 p.Trp590Ser 19202195:165:10
status: NEW173 Time-dependent apoA-I dissociation from cells expressing ABCA1 or ABCA1-W590S.
X
ABCA1 p.Trp590Ser 19202195:173:4
status: NEWX
ABCA1 p.Trp590Ser 19202195:173:72
status: NEW174 HEK/ABCA1-GFP and HEK/ABCA1-W590S-GFP cells were incubated with 5 mg/ml Alexa546-labeled apoA-I for 15 min at 37°C and further incubated with 25 mg/ml nonlabeled apoA-I for the indicated times at 27°C.
X
ABCA1 p.Trp590Ser 19202195:174:28
status: NEW178 The W590S mutation retarded the dissociation of apoA-I from ABCA1.
X
ABCA1 p.Trp590Ser 19202195:178:4
status: NEW186 In addition, ABCA1-W590S was reported not to be stabilized by apoA-I (29).
X
ABCA1 p.Trp590Ser 19202195:186:19
status: NEWX
ABCA1 p.Trp590Ser 19202195:186:31
status: NEW189 Our results suggest that the W590S mutation impaired NaTC-dependent lipid efflux but not apoA-I binding.
X
ABCA1 p.Trp590Ser 19202195:189:29
status: NEW191 These results suggest that the W590S mutation impairs ATP-dependent lipid translocation and that lipid translocation or possibly lipid loading facilitates apoA-I dissociation from ABCA1.
X
ABCA1 p.Trp590Ser 19202195:191:31
status: NEW5 The Tangier disease mutation W590S, which resides in the extracellular domain and impairs apoA-I-dependent lipid efflux, greatly decreased NaTC-dependent cholesterol and phospholipid efflux.
X
ABCA1 p.Trp590Ser 19202195:5:29
status: NEW43 Plasmids The expression vectors for wild-type ABCA1, ABCA1-W590S, and ABCA1-K939M,K1952M (MM), fused to GFP at their C termini, were generated as described previously (3, 18).
X
ABCA1 p.Trp590Ser 19202195:43:59
status: NEW96 The W590S Tangier mutation impairs NaTC-dependent lipid efflux but not apoA-I binding It has been reported that ABCA1 carrying the Tangier disease mutation W590S in the first extra cellular domain is correctly targeted to the plasma membrane and interacts with apoA-I but fails to mediate normal apoA-I-dependent lipid efflux (3, 26-28).
X
ABCA1 p.Trp590Ser 19202195:96:4
status: NEWX
ABCA1 p.Trp590Ser 19202195:96:156
status: NEW97 We compared NaTC-dependent lipid efflux from HEK293 cells stably expressing wild-type or ABCA1-W590S fused to GFP at the C terminus.
X
ABCA1 p.Trp590Ser 19202195:97:95
status: NEW98 Western blotting (Fig. 4A) and fluorescence microscopy (see supplementary Fig. II) suggested that the expression and surface localization of the wild type and ABCA1-W590S were similar.
X
ABCA1 p.Trp590Ser 19202195:98:165
status: NEW99 Both NaTC-dependent and apoA-I-dependent cholesterol and phospholipid efflux were greatly decreased by the W590S mutation (Fig. 4B, C).
X
ABCA1 p.Trp590Ser 19202195:99:107
status: NEW100 As previously reported, apoA-I bound to the cell surface expressing ABCA1-W590S as efficiently as to that expressing wild-type ABCA1 (see supplementary Fig. II).
X
ABCA1 p.Trp590Ser 19202195:100:74
status: NEW114 1168 Journal of Lipid Research Volume 50, 2009 at SEMMELWEIS EGYETEM NET KORELET, on December 3, 2015 www.jlr.org Downloaded from .DC1.html are mediated by ABCA1 in an ATP-dependent manner, are in fact separable and that the W590S mutation impairs only the latter step.
X
ABCA1 p.Trp590Ser 19202195:114:226
status: NEW122 The kinetics of apoA-I binding to cells expressing ABCA1-W590S was quite similar to that to cells expressing wild-type ABCA1.
X
ABCA1 p.Trp590Ser 19202195:122:57
status: NEW125 These results suggest that the W590S mutation retards apoA-I dissociation from cells.
X
ABCA1 p.Trp590Ser 19202195:125:31
status: NEW133 The W590S mutation impairs NaTC-dependent lipid efflux by ABCA1.
X
ABCA1 p.Trp590Ser 19202195:133:4
status: NEW136 The efflux of cellular free cholesterol (B) and choline phospholipids (C) was analyzed. HEK/ABCA1-GFP cells and HEK/ ABCA1-W590S-GFP cells were incubated for 24 h in DMEM containing 0.02% BSA (open bars), 0.02% BSA and 1 mM NaTC (filled bars), or 0.02% BSA and 5 mg/ml apoA-I (hatched bars).
X
ABCA1 p.Trp590Ser 19202195:136:123
status: NEW139 HEK/ABCA1-GFP, HEK/ABCA1-MM-GFP, or HEK/ABCA1-W590S-GFP cells were incubated with 5 mg/ml Alexa546-labeled apoA-I for the indicated times at 27&#b0;C.
X
ABCA1 p.Trp590Ser 19202195:139:46
status: NEW149 Alternatively, binding of significant amounts of apoA-I on the cell surface may cause spontaneous cholesterol loading on apoA-I. Indeed, greater cholesterol efflux was observed in the presence of apoA-I from cells expressing ABCA1-W590S, which allows apoA-I binding, than in the presence of NaTC, and this effect was strongly suppressed at 27&#b0;C (Fig. 4; see supplementary Fig. VI).
X
ABCA1 p.Trp590Ser 19202195:149:231
status: NEW156 The Tangier mutation W590S, which impairs apoA-I-dependent lipid efflux, greatly decreased NaTC-dependent cholesterol and phospholipid efflux.
X
ABCA1 p.Trp590Ser 19202195:156:21
status: NEW157 It has been reported that ABCA1-W590S interacts in a normal manner with ATP (3).
X
ABCA1 p.Trp590Ser 19202195:157:32
status: NEW158 The W590S mutation may abolish the coupling of ATP-induced conformational changes of ABCA1 with lipid translocation.
X
ABCA1 p.Trp590Ser 19202195:158:4
status: NEW159 The kinetics of apoA-I binding to cells expressing ABCA1-W590S were similar to those of binding to cells expressing wild-type ABCA1, consistent with a previous report showing that the W590S mutation does not impair apoA-I binding (8, 26-28).
X
ABCA1 p.Trp590Ser 19202195:159:57
status: NEWX
ABCA1 p.Trp590Ser 19202195:159:184
status: NEW160 Thus, the W590S mutation would not affect the conformational changes of ABCA1 Fig. 7.
X
ABCA1 p.Trp590Ser 19202195:160:10
status: NEW168 Time-dependent apoA-I dissociation from cells expressing ABCA1 or ABCA1-W590S.
X
ABCA1 p.Trp590Ser 19202195:168:72
status: NEW169 HEK/ABCA1-GFP and HEK/ABCA1-W590S-GFP cells were incubated with 5 mg/ml Alexa546-labeled apoA-I for 15 min at 37&#b0;C and further incubated with 25 mg/ml nonlabeled apoA-I for the indicated times at 27&#b0;C.
X
ABCA1 p.Trp590Ser 19202195:169:28
status: NEW181 In addition, ABCA1-W590S was reported not to be stabilized by apoA-I (29).
X
ABCA1 p.Trp590Ser 19202195:181:19
status: NEW184 Our results suggest that the W590S mutation impaired NaTC-dependent lipid efflux but not apoA-I binding.
X
ABCA1 p.Trp590Ser 19202195:184:29
status: NEW
PMID: 19258317
[PubMed]
Hozoji M et al: "Formation of two intramolecular disulfide bonds is necessary for ApoA-I-dependent cholesterol efflux mediated by ABCA1."
No.
Sentence
Comment
192
The Tangier mutation W590S impairs apoA-I-dependent cholesterol efflux but not apoA-I binding (15).
X
ABCA1 p.Trp590Ser 19258317:192:21
status: NEW193 The replacement of C15 by serine may cause conformational changes similar to those caused by the W590S mutation.
X
ABCA1 p.Trp590Ser 19258317:193:97
status: NEW190 The Tangier mutation W590S impairs apoA-I-dependent cholesterol efflux but not apoA-I binding (15).
X
ABCA1 p.Trp590Ser 19258317:190:21
status: NEW191 The replacement of C15 by serine may cause conformational changes similar to those caused by the W590S mutation.
X
ABCA1 p.Trp590Ser 19258317:191:97
status: NEW
PMID: 19170766
[PubMed]
Azuma Y et al: "Retroendocytosis pathway of ABCA1/apoA-I contributes to HDL formation."
No.
Sentence
Comment
36
A Tangier disease-type mutation (W590S) greatly reduced the cholesterol efflux activity of ABCA1(207HA), and lysine-to-methionine mutations (MM) in both of the two ATP-binding domains almost completely abolished activity (Fig. 1E), as we previously reported in the context of ABCA1 or ABCA1-GFP (Tanaka et al. 2003).
X
ABCA1 p.Trp590Ser 19170766:36:33
status: NEW37 As shown in Fig. S1 in Supporting Information/Supplementary material, the subcellular localization and cell surface expression of the W590S and MM mutants of ABCA1(207HA) (lower panels) were indistinguishable from those of the corresponding mutants of ABCA1-GFP.
X
ABCA1 p.Trp590Ser 19170766:37:134
status: NEW197 DNA construction We constructed plasmids for expressing human wild-type ABCA1, ABCA1(W590S) and ABCA1(K939M,K1952M)(MM) bearing an insertion of the influenza virus hemagglutinin (HA) epitope sequence between residues 207 and 208 (within the first extracellular loop), using the bicistronic expression vector pHaMAIRESneo.
X
ABCA1 p.Trp590Ser 19170766:197:85
status: NEW
PMID: 18776170
[PubMed]
Vaughan AM et al: "ABCA1 mutants reveal an interdependency between lipid export function, apoA-I binding activity, and Janus kinase 2 activation."
No.
Sentence
Comment
49
the first extracellular loop (V399A, R587W, W590S, and Q597R), two were in the second extracellular loop (C1477R and I1517R), and one was in the Walker A motif of the first nucleotide binding domain (A937V, NBD1) (Fig. 1).
X
ABCA1 p.Trp590Ser 18776170:49:44
status: NEW55 W590S.A1950V.
X
ABCA1 p.Trp590Ser 18776170:55:0
status: NEW82 This activation was nearly abolished in cells expressing all mutants except two (W590S and A1950V), which are the same two mutants that have the highest ability to cross-link apoA-I (Fig. 2E).
X
ABCA1 p.Trp590Ser 18776170:82:81
status: NEW96 Fitzgerald et al. (24) reported similar cell surface localizations for mutants R587W, W590S, Q597R, and C1477R.
X
ABCA1 p.Trp590Ser 18776170:96:86
status: NEW113 Cholesterol and phospholipid efflux values for mutant W590S are labeled in panels A and B.
X
ABCA1 p.Trp590Ser 18776170:113:54
status: NEW126 A previous study showed that the W590S ABCA1 mutation severely impaired lipid efflux without affecting apoA-I cross-linking to ABCA1 (24), suggesting that apoA-I binding to ABCA1 can be dissociated from lipid export activity.
X
ABCA1 p.Trp590Ser 18776170:126:33
status: NEW129 The lipid export activity of the W590S ABCA1 mutant, however, was among the highest of the natural mutants, and thus values for cells expressing this mutant ABCA1 did not deviate far from the linear regression line when lipid transport activities were plotted against apoA-I/ABCA1 cross-linking (Fig. 4A, B).
X
ABCA1 p.Trp590Ser 18776170:129:33
status: NEW133 The two ABCA1 mutants that had near-normal apoA-I-induced JAK2 activation were W590S Fig. 6.
X
ABCA1 p.Trp590Ser 18776170:133:79
status: NEW95 Fitzgerald et al. (24) reported similar cell surface localizations for mutants R587W, W590S, Q597R, and C1477R.
X
ABCA1 p.Trp590Ser 18776170:95:86
status: NEW112 Cholesterol and phospholipid efflux values for mutant W590S are labeled in panels A and B.
X
ABCA1 p.Trp590Ser 18776170:112:54
status: NEW125 A previous study showed that the W590S ABCA1 mutation severely impaired lipid efflux without affecting apoA-I cross-linking to ABCA1 (24), suggesting that apoA-I binding to ABCA1 can be dissociated from lipid export activity.
X
ABCA1 p.Trp590Ser 18776170:125:33
status: NEW128 The lipid export activity of the W590S ABCA1 mutant, however, was among the highest of the natural mutants, and thus values for cells expressing this mutant ABCA1 did not deviate far from the linear regression line when lipid transport activities were plotted against apoA-I/ABCA1 cross-linking (Fig. 4A, B).
X
ABCA1 p.Trp590Ser 18776170:128:33
status: NEW132 The two ABCA1 mutants that had near-normal apoA-I-induced JAK2 activation were W590S Fig. 6.
X
ABCA1 p.Trp590Ser 18776170:132:79
status: NEW
PMID: 18343215
[PubMed]
Tanaka AR et al: "The ABCA1 Q597R mutant undergoes trafficking from the ER upon ER stress."
No.
Sentence
Comment
116
Previously, we reported that the W590S mutant of ABCA1 shows functional defects, but is localized to the PM [17].
X
ABCA1 p.Trp590Ser 18343215:116:33
status: NEW142 W590S mutation and the Q597R mutation are within extracellular domain 1 (the ER-lumenal domain) of ABCA1, which is a mutational hotspot in TD.
X
ABCA1 p.Trp590Ser 18343215:142:0
status: NEW115 Previously, we reported that the W590S mutant of ABCA1 shows functional defects, but is localized to the PM [17].
X
ABCA1 p.Trp590Ser 18343215:115:33
status: NEW141 W590S mutation and the Q597R mutation are within extracellular domain 1 (the ER-lumenal domain) of ABCA1, which is a mutational hotspot in TD.
X
ABCA1 p.Trp590Ser 18343215:141:0
status: NEW
PMID: 17655203
[PubMed]
Mukhamedova N et al: "The role of different regions of ATP-binding cassette transporter A1 in cholesterol efflux."
No.
Sentence
Comment
269
Natural mutations found in the Tangier pedigree, R587W, W590S, Q597R, and S1506L, as well as generated mutant C1477R strongly inhibited cholesterol and phospholipid efflux (28, 35, 36) and, with the exception of W590S, also apoA-I binding (36).
X
ABCA1 p.Trp590Ser 17655203:269:56
status: NEWX
ABCA1 p.Trp590Ser 17655203:269:212
status: NEW288 Other mutations (e.g., W590S) inhibited cholesterol efflux with apoA-I binding intact (30, 35, 36).
X
ABCA1 p.Trp590Ser 17655203:288:23
status: NEW315 As with the ABCA1 mutant W590S (35, 36), the antibody NDF4C2 inhibited cholesterol efflux without affecting apoA-I binding to ABCA1.
X
ABCA1 p.Trp590Ser 17655203:315:25
status: NEW
PMID: 17303779
[PubMed]
Kiss RS et al: "Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects."
No.
Sentence
Comment
47
In ABCA1, a total of 19 nonsynonymous coding sequence variants; some of these we reported previously.22 Of these, 9 sequence variants were common polymorphisms (ie, reported in the literature as common or of similar prevalence in control subjects): P85L, P85A, R219K, V399A, V771M, V825I, I883M, E1172D, R1587K.14,32-35 Another 5 sequence variants, identified here, were previously reported to be disease causing: W590L (reported as W590S)14; C1477F (reported as C1477R)13; S1731C (only found in French-Canadian populations)36; N1800H32; and 1851X.37 Five sequence variants were novel: K199F, H551D, R965C, E1386Q, and D1706N.
X
ABCA1 p.Trp590Ser 17303779:47:433
status: NEW42 In ABCA1, a total of 19 nonsynonymous coding sequence variants; some of these we reported previously.22 Of these, 9 sequence variants were common polymorphisms (ie, reported in the literature as common or of similar prevalence in control subjects): P85L, P85A, R219K, V399A, V771M, V825I, I883M, E1172D, R1587K.14,32-35 Another 5 sequence variants, identified here, were previously reported to be disease causing: W590L (reported as W590S)14; C1477F (reported as C1477R)13; S1731C (only found in French-Canadian populations)36; N1800H32; and 1851X.37 Five sequence variants were novel: K199F, H551D, R965C, E1386Q, and D1706N.
X
ABCA1 p.Trp590Ser 17303779:42:433
status: NEW
PMID: 17324574
[PubMed]
Attie AD et al: "ABCA1: at the nexus of cholesterol, HDL and atherosclerosis."
No.
Sentence
Comment
142
This is supported by studies of the Trp590Ser ABCA1 mutant, which binds to apo-A1 but does not promote efficient cholesterol efflux and releases the apo-A1 in an unlipidated form [70,71].
X
ABCA1 p.Trp590Ser 17324574:142:36
status: NEW155 This is also true of the Trp590Ser mutant mentioned earlier.
X
ABCA1 p.Trp590Ser 17324574:155:25
status: NEW156 Mutations in the ATP-binding modules of the Trp590Ser mutant prevent binding to apo-A1 [69], predicting that the multimeric form is the one bound by apo-A1.
X
ABCA1 p.Trp590Ser 17324574:156:44
status: NEW
PMID: 16873719
[PubMed]
Singaraja RR et al: "Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid phenotypes both in vivo and in vitro."
No.
Sentence
Comment
43
In ABCA1 heterozygotes, 3 distinct phenotypic groups emerged, one in which HDL-C levels were Ϸ50% of those of age-and sex-matched controls, one in which HDL-C levels were at least 70% of controls (A255T, W590S, T929I), and one in which HDL-C levels were significantly below the expected 50% of the levels for controls (30.4% of controls) (M1091T) (Table).
X
ABCA1 p.Trp590Ser 16873719:43:210
status: NEW111 Three mutations fit this criteria, with patients harboring A255T showing 76%, W590S showing 83%, and T929I showing 76% of normal HDL-C levels.
X
ABCA1 p.Trp590Ser 16873719:111:78
status: NEW112 Intracellular Localization All 3 mutants A255T, W590S, and T929I, were localized by immunofluorescence to the plasma membrane and to intracellular regions in a manner indistinguishable from wild-type ABCA1 (Figure 5A).
X
ABCA1 p.Trp590Ser 16873719:112:48
status: NEW115 ApoA-I Binding All mutants showed normal ApoA-I binding compared with wild-type ABCA1 (A255T, 98.0Ϯ10.2%, nϭ4; W590S, 94.9Ϯ26.7%, nϭ3; T929I, 83.6Ϯ14.5, nϭ3) (Figure 5D).
X
ABCA1 p.Trp590Ser 16873719:115:123
status: NEW116 Cholesterol and Phosphocholine Efflux All 3 mutants displayed defects in both cholesterol (Figure 5E) and phosphocholine (Figure 5F) efflux (A255T, cholesterol 49.2Ϯ7.7%, nϭ5, Pϭ0.0001, choline 41.5Ϯ22.5%, nϭ8, Pϭ0.0002; W590S, cholesterol 47.1Ϯ13.1%, nϭ5, Pϭ0.0008, choline 44.7Ϯ21.1%, nϭ3, PϽ0.05; and T929I, Figure 4.
X
ABCA1 p.Trp590Ser 16873719:116:257
status: NEW125 Mutant W590S has been previously shown to induce reduced annexin V binding, which is a measure of plasma membrane flipping.18 Plasma membrane flipping is observed in wild-type ABCA1-expressing cells and may be a critical factor for efflux to occur.
X
ABCA1 p.Trp590Ser 16873719:125:7
status: NEW126 Recent work has shown that W590S associates normally with ApoA-I. However, the ApoA-I released from wild-type ABCA1 was bound to lipids, whereas the ApoA-I released from W590S was lipid-free, indicating a defect in the lipidation of ApoA-I.24 When the ability of the ABCA1 mutants to promote ␣HDL formation was assessed (Figure 5G), wild-type ABCA1 was able to form ␣HDL of 10.4 to 12.2 nM diameter, whereas A255T and W590S formed only lipid-free ApoA-I and T929I formed lipid-free and ApoA-I of 7.1 to Ϸ9-nM diameter.
X
ABCA1 p.Trp590Ser 16873719:126:27
status: NEWX
ABCA1 p.Trp590Ser 16873719:126:170
status: NEWX
ABCA1 p.Trp590Ser 16873719:126:430
status: NEW132 Heterozygous patients with the mutations A255T, W590S and T929I show Ͼ70% of normal HDL-C levels, and therefore are hypothesized to have mutant alleles that partially retain function.
X
ABCA1 p.Trp590Ser 16873719:132:48
status: NEW135 C, Cell surface biotinylation revealed normal levels of A255T, W590S, and T929I at the plasma membrane.
X
ABCA1 p.Trp590Ser 16873719:135:63
status: NEW161 All 3 missense mutations (A255T, W590S, and T929I) that showed residual function were localized to the plasma membrane and induced cell surface ApoA-I binding at levels similar to wild-type ABCA1.
X
ABCA1 p.Trp590Ser 16873719:161:33
status: NEW162 Our findings for the mutant W590S therefore agree with previous findings that W590S does localize normally and shows normal ApoA-I binding.18,19,25 These data imply that although mutant ABCA1 localizes to the plasma membrane and induces ApoA-I binding, these events are insufficient for normal lipid efflux to occur.
X
ABCA1 p.Trp590Ser 16873719:162:28
status: NEWX
ABCA1 p.Trp590Ser 16873719:162:78
status: NEW163 Previous studies showed that W590S, which has defective lipid efflux, cross-links efficiently to ApoA-I ,and its rate of dissociation from ApoA-I was similar to wild-type ABCA1.24 However, the ApoA-I released from wild-type ABCA1 was bound to lipids, whereas the ApoA-I released from W590S was lipid-free.24 Mutants A255T, W590S, and T929I were normal in their binding to lipid-free ApoA-I. However, A255T and W590S failed completely to lipidate ApoA-I, and T929I produced lipidated species with abnormal size.
X
ABCA1 p.Trp590Ser 16873719:163:29
status: NEWX
ABCA1 p.Trp590Ser 16873719:163:33
status: NEWX
ABCA1 p.Trp590Ser 16873719:163:284
status: NEWX
ABCA1 p.Trp590Ser 16873719:163:323
status: NEW164 One mutant, M1091T, when present in heterozygous patients, results in significantly lower than 50% of normal HDL-C and efflux levels.
X
ABCA1 p.Trp590Ser 16873719:164:28
status: NEWX
ABCA1 p.Trp590Ser 16873719:164:78
status: NEW165 Previous studies showed that W590S, which has defective lipid efflux, cross-links efficiently to ApoA-I ,and its rate of dissociation from ApoA-I was similar to wild-type ABCA1.24 However, the ApoA-I released from wild-type ABCA1 was bound to lipids, whereas the ApoA-I released from W590S was lipid-free.24 Mutants A255T, W590S, and T929I were normal in their binding to lipid-free ApoA-I. However, A255T and W590S failed completely to lipidate ApoA-I, and T929I produced lipidated species with abnormal size.
X
ABCA1 p.Trp590Ser 16873719:165:29
status: NEWX
ABCA1 p.Trp590Ser 16873719:165:284
status: NEWX
ABCA1 p.Trp590Ser 16873719:165:323
status: NEWX
ABCA1 p.Trp590Ser 16873719:165:410
status: NEW
PMID: 16709568
[PubMed]
Trompier D et al: "Transition from dimers to higher oligomeric forms occurs during the ATPase cycle of the ABCA1 transporter."
No.
Sentence
Comment
128
We chose to analyze W590S and C1477R, two Tangier-associated mutations previously characterized and known to differentially affect the ABCA1-induced binding of apoA-I and annexin V (3, 32).
X
ABCA1 p.Trp590Ser 16709568:128:20
status: NEW133 A:D ratio < 2.5 A:D ratio > 2.5 N-ter 14.86 Ϯ 1.4 19.11 Ϯ 1.3 YABCA1/CABCA1 n ϭ 11 n ϭ 17 Nand C-ter 17.72 Ϯ 2.1 18.91 Ϯ 2.312 C Y ABCA1/ABCA1 Y C n ϭ 11 n ϭ 8 C-ter 11.74 Ϯ 0.85 24.00 Ϯ 1.001 ABCA1Y/ABCA1C n ϭ 29 n ϭ 21 W590S 11.79 Ϯ 1.230 26.54 Ϯ 1.004 W590SY/W590SC n ϭ 12 n ϭ 30 C1477R 13.70 Ϯ 0.7299 26.50 Ϯ 1.462 C1477RY/C1477RC n ϭ 27 n ϭ 22 ABCA1MM 11.83 Ϯ 1.048 26.59 Ϯ 1.591 ABCA1MMY/ABCA1MMC n ϭ 14 n ϭ 15 Oligomerization of the ABCA1 Transporter 20286 constructs supported dimerization since an efficiency of the energy transfer similar to that of wild type and similarly sensitive to variations in acceptor-to-donor ratios was detected (Fig. 4, A and B, and Table 1).
X
ABCA1 p.Trp590Ser 16709568:133:82
status: NEWX
ABCA1 p.Trp590Ser 16709568:133:293
status: NEW134 However, upon fractionation on native PAGE, the lysates of cells transfected with W590S or C1477R showed a higher molecular mass band migrating at Ͼ800 kDa and accounting for 9 and 27%, respectively, of the total ABCA1 signal (Fig. 4C, upper panel), in the absence of any modification of expression levels as shown by the SDS-PAGE analysis (Fig. 4C, lower panel).
X
ABCA1 p.Trp590Ser 16709568:134:82
status: NEW180 A and B, imaging FRET of cells expressing appropriately tagged W590S or C1477R, two ABCA1 variants associated with Tangier disease and variably affecting the functional readouts associated with ABCA1 expression.
X
ABCA1 p.Trp590Ser 16709568:180:63
status: NEW182 C, upper panel, native PAGE profiles of lysates from cells transfected with ABCA1Y, W590S, W590SY, or C1477RY indicate that the two variants associated in dimers.
X
ABCA1 p.Trp590Ser 16709568:182:84
status: NEW127 We chose to analyze W590S and C1477R, two Tangier-associated mutations previously characterized and known to differentially affect the ABCA1-induced binding of apoA-I and annexin V (3, 32).
X
ABCA1 p.Trp590Ser 16709568:127:20
status: NEW132 A:D ratio < 2.5 A:D ratio > 2.5 N-ter 14.86 afe; 1.4 19.11 afe; 1.3 YABCA1/CABCA1 n afd; 11 n afd; 17 Nand C-ter 17.72 afe; 2.1 18.91 afe; 2.312 C Y ABCA1/ABCA1 Y C n afd; 11 n afd; 8 C-ter 11.74 afe; 0.85 24.00 afe; 1.001 ABCA1Y/ABCA1C n afd; 29 n afd; 21 W590S 11.79 afe; 1.230 26.54 afe; 1.004 W590SY/W590SC n afd; 12 n afd; 30 C1477R 13.70 afe; 0.7299 26.50 afe; 1.462 C1477RY/C1477RC n afd; 27 n afd; 22 ABCA1MM 11.83 afe; 1.048 26.59 afe; 1.591 ABCA1MMY/ABCA1MMC n afd; 14 n afd; 15 Oligomerization of the ABCA1 Transporter 20286 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281ߦNUMBER 29ߦJULY 21, 2006 at SEMMELWEIS UNIV OF MEDICINE on December 3, constructs supported dimerization since an efficiency of the energy transfer similar to that of wild type and similarly sensitive to variations in acceptor-to-donor ratios was detected (Fig. 4, A and B, and Table 1).
X
ABCA1 p.Trp590Ser 16709568:132:293
status: NEW179 A and B, imaging FRET of cells expressing appropriately tagged W590S or C1477R, two ABCA1 variants associated with Tangier disease and variably affecting the functional readouts associated with ABCA1 expression.
X
ABCA1 p.Trp590Ser 16709568:179:63
status: NEW181 C, upper panel, native PAGE profiles of lysates from cells transfected with ABCA1Y, W590S, W590SY, or C1477RY indicate that the two variants associated in dimers.
X
ABCA1 p.Trp590Ser 16709568:181:84
status: NEW
PMID: 16798073
[PubMed]
Cavelier C et al: "Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1."
No.
Sentence
Comment
129
All ABCA1 mutants - except ABCA1(W590S) - which fail to promote cholesterol efflux also fail to cross-link apoA-I [55,56].
X
ABCA1 p.Trp590Ser 16798073:129:33
status: NEW131 Interestingly, the ABCA1 (W590S) mutant cross-links apoA-I better than the wild-type ABCA1 but fails to mediate cholesterol efflux.
X
ABCA1 p.Trp590Ser 16798073:131:26
status: NEW136 The carboxy-terminal truncation mutant however showed reduced binding affinity to normal ABCA1 and ABCA1 (W590S).
X
ABCA1 p.Trp590Ser 16798073:136:106
status: NEW130 All ABCA1 mutants - except ABCA1(W590S) - which fail to promote cholesterol efflux also fail to cross-link apoA-I [55,56].
X
ABCA1 p.Trp590Ser 16798073:130:33
status: NEW132 Interestingly, the ABCA1 (W590S) mutant cross-links apoA-I better than the wild-type ABCA1 but fails to mediate cholesterol efflux.
X
ABCA1 p.Trp590Ser 16798073:132:26
status: NEW137 The carboxy-terminal truncation mutant however showed reduced binding affinity to normal ABCA1 and ABCA1 (W590S).
X
ABCA1 p.Trp590Ser 16798073:137:106
status: NEW
PMID: 16443932
[PubMed]
Nofer JR et al: "Apolipoprotein A-I activates Cdc42 signaling through the ABCA1 transporter."
No.
Sentence
Comment
191
These findings suggest that ABCA1-DC is able to bind apoA-I in a nearly normal manner but that this process can be uncoupled from the ABCA1-mediated outside-in signaling and the transfer of cholesterol to apoA-I. Likewise, Fitzgerald et al. (7) reported that the W590S ABCA1 mutant is fully competent to form complexes with apoA-I but fails to efflux cholesterol normally.
X
ABCA1 p.Trp590Ser 16443932:191:263
status: NEW189 These findings suggest that ABCA1-DC is able to bind apoA-I in a nearly normal manner but that this process can be uncoupled from the ABCA1-mediated outside-in signaling and the transfer of cholesterol to apoA-I. Likewise, Fitzgerald et al. (7) reported that the W590S ABCA1 mutant is fully competent to form complexes with apoA-I but fails to efflux cholesterol normally.
X
ABCA1 p.Trp590Ser 16443932:189:263
status: NEW
PMID: 16501936
[PubMed]
Zannis VI et al: "Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL."
No.
Sentence
Comment
147
In vitro analysis of the effects on apoA-I/ABCA1 interactions (cross-linking assay) by mutations in ABCA1 that are found in Tangier disease patients and diminish lipid efflux [71] showed that cross-linking was dramatically reduced to 5-10% of the WT control for three mutants (Gln597Arg, Cys1477Arg, and Ser1506Leu), reduced by 50% for the Arg587Trp mutant, and was remarkably increased to 125% of control for the Trp590Ser mutant [71].
X
ABCA1 p.Trp590Ser 16501936:147:414
status: NEW148 Additional analysis of interactions of the mutant forms of apoA-I with the Trp590Ser mutant raised the possibility that the Trp590Ser mutation may have altered the environment in the binding site of ABCA1 in a way that prevented efficient lipid efflux despite the increased binding [73].
X
ABCA1 p.Trp590Ser 16501936:148:75
status: NEWX
ABCA1 p.Trp590Ser 16501936:148:124
status: NEW163 ApoA-I/ABCA1 binding, which exhibits a half-life of approximately 30 min [77], appears to be a necessary but not sufficient step for lipid efflux (see description of the Trp590Ser mutant above) [33, 34, 71, 80].
X
ABCA1 p.Trp590Ser 16501936:163:170
status: NEW165 This appears to require the formation of a productive complex between apoA-I and ABCA1 because in the case of the ABCA1 [Trp590Ser] mutant that is associated with Tangier disease [31, 32, 71], an apoA1/ABCA1 complex is formed but the apoA-I is not lipidated and is subsequently released in a lipid-free form [77].
X
ABCA1 p.Trp590Ser 16501936:165:123
status: NEW264 For instance, the binding of WT apoA-I to ABCA1[Trp590Ser] may not be productive and as a consequence, results in defective lipid efflux.
X
ABCA1 p.Trp590Ser 16501936:264:48
status: NEW
PMID: 16704350
[PubMed]
Brunham LR et al: "Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis."
No.
Sentence
Comment
550
However, a subset of mutations are associated with greater than 50% of control HDL levels, specifically T929I, A947V, R1680W, and W590S.
X
ABCA1 p.Trp590Ser 16704350:550:130
status: NEW555 Since a complete loss of function allele would be expected to result in a 50% reduction in HDL levels, a greater than 50% reduction in HDL is most likely explained by a dominant negative allele, in which TABLE 3 Patient phenotypes associated with heterozygous ABCA1 mutations Mutation HDL (mmol/L) HDL (% of control) Number of patients M1091T 0.48 ± 0.5 30 ± 30 4 G1216V 0.50 40 1 R2144X 0.56 ± 0.2 41 ± 18 12 R282X 0.52 41 1 R909X 0.59 ± 0.3 42 ± 19 5 K776N 0.55 ± 0.1 47 ± 5 2 R587W 0.61 ± 0.1 47 ± 8 7 S364C 0.60 48 1 P1065S 0.80 51 1 c-ter deletion 0.75 53 1 N1800H - 56.5 33 P85L 0.72 ± 0.4 57 ± 33 5 Del693L 0.79 ± 0.2 57 ± 15 8 D1289N 0.80 ± 0.1 59 ± 12 4 R2081W 0.80 ± 0.1 59 ± 12 4 2203X 0.80 ± 0.2 59 ± 20 4 DelED1893,4 0.77 ± 0.2 59 ± 18 8 2145X 0.82 ± 0.1 59 ± 9 4 A1046D 0.70 ± 0.1 60 ± 8 2 Q597R 0.82 ± 0.1 60 ± 5 5 C1477R 0.82 ± 0.2 61 ± 15 9 IVS25 + 1G > C 0.78 ± 0.1 62 ± 12 4 D1099Y 0.83 ± 0.3 63 ± 21 5 1552X 1.00 64 1 F2009S 0.82 ± 0.2 64 ± 19 6 R587W 0.86 ± 0.1 65 ± 17 2 R1068H 0.90 ± 0.3 67 ± 26 9 N935S 1.00 ± 0.3 74 ± 16 7 T929I 1.01 ± 0.2 76 ± 7 8 1284X 1.11 ± 0.2 83 ± 14 5 A937V 1.15 ± 0.6 85 ± 28 2 R1680W 1.22 ± 0.2 87 ± 17 3 635X 1.24 ± 0.5 90 ± 32 7 W590S 1.32 ± 0.6 103 ± 46 15 the mutant protein actually interferes with the activity of the remaining wild-type protein.
X
ABCA1 p.Trp590Ser 16704350:555:1445
status: NEW
PMID: 16429166
[PubMed]
Brunham LR et al: "Accurate prediction of the functional significance of single nucleotide polymorphisms and mutations in the ABCA1 gene."
No.
Sentence
Comment
48
This SNP has been reported to be associated with decreased HDL cholesterol and increased severity of atherosclerosis in Table 1. subPSEC Scores and Probability of Functional Impairment (Pdeleterious) for ABCA1 Mutations and SNPs Mutations SNPs Variant SubPSEC Pdeleterious Variant subPSEC Pdeleterious P85L À4.62 0.83 R219K À0.57 0.08 H160F À2.79 0.45 V399A À2.26 0.32 R230C À4.27 0.78 V771M À2.86 0.46 A255T À1.81 0.23 T774P À1.99 0.27 E284K À2.34 0.34 K776N À3.53 0.63 Y482C À4.21 0.77 V825I À1.06 0.13 R587W À6.04 0.95 I883M À1.38 0.17 W590S À5.19 0.9 E1172D À1.96 0.26 W590L À4.48 0.82 R1587K À0.58 0.08 Q597R À7.15 0.98 S1731C À4.21 0.77 T929I À4.29 0.78 N935H À8.54 1 N935S À7.53 0.99 A937V À6.6 0.97 A1046D À7.52 0.99 M1091T À3.56 0.64 D1099Y À6.09 0.96 D1289N À2.48 0.37 L1379F À3.81 0.69 C1477R À5.44 0.92 S1506L À5.17 0.9 N1611D À5.69 0.94 R1680W À6.02 0.95 V1704D À3.21 0.55 N1800H À4.23 0.77 R1901S À5.06 0.89 F2009S À2.73 0.43 R2081W À8.08 0.99 P2150L À2.88 0.47 Q2196H À2.74 0.43 DOI: 10.1371/journal.pgen.0010083.t001 PLoS Genetics | www.plosgenetics.org December 2005 | Volume 1 | Issue 6 | e83 0740 Accurate Prediction of ABCA1 Variants Synopsis A major goal of human genetics research is to understand how genetic variation leads to differences in the function of genes.
X
ABCA1 p.Trp590Ser 16429166:48:539
status: NEWX
ABCA1 p.Trp590Ser 16429166:48:609
status: NEW75 Cholesterol Efflux Values for 293 Cells Transfected with ABCA1 Variants and subPSEC and PolyPhen Predictions of the Functional Impact of these Variants Variant Variant Type subPSEC Cholesterol Efflux PolyPhen R2081W Mutation À8.08 21.1 6 21%* Probably damaging N935S Mutation À7.53 29.3 6 13%* Benign A1046D Mutation À7.52 16.8 6 7%* Possibly damaging Q597R Mutation À7.15 17.7 6 14%* Probably damaging R587W Mutation À6.04 31.7 6 33%* Probably damaging C1477R Mutation À5.44 20.5 6 10%* Probably damaging W590S Mutation À5.19 47.1 6 13%* Probably damaging S1506L Mutation À5.17 17.8 6 15%* Probably damaging T929I Mutation À4.29 69.9 6 11%* Possibly damaging N1800H Mutation À4.23 31.3 6 16%* Possibly damaging S1731C SNP À4.21 12.3 6 10%* Possibly damaging M1091T Mutation À3.56 6.9 6 20%* Probably damaging P2150L Mutation À2.88 88.4 6 21% Probably damaging V771M SNP À2.86 145.4 6 33% Benign D1289N Mutation À2.48 137.7 6 86% Benign I883M SNP À1.38 69.1 6 16%* Benign R219K SNP À0.57 103.7 6 21.05 Benign Wild-type - 0.0 100% - *p , 0.01 compared to wild-type ABCA1.
X
ABCA1 p.Trp590Ser 16429166:75:506
status: NEWX
ABCA1 p.Trp590Ser 16429166:75:536
status: NEW110 DOI: 10.1371/journal.pgen.0010083.g003 Table 3. subPSEC Scores for ABCA1 Variants Described in a Cohort of Individuals with Low HDL Cholesterol from the General Population Variant subPSEC Score Macrophage Efflux PolyPhen D1706N À6.57 0.38a Possibly damaging C1477F À5.55 0.34a Probably damaging W590S À5.19 - Probably damaging H551D À4.99 0.32a Probably damaging P85L À4.62 0.8 Probably damaging W590L À4.48 0.31a Probably damaging N1800H À4.23 0.27a Possibly damaging R965C À4.22 0.59 Probably damaging S1731C À4.21 0.28a Possibly damaging A1670T À4.2 - Possibly damaging K401Q À4.2 - Benign T459P À4.11 0.28a Possibly damaging R638Q À4.08 - Possibly damaging L1026P À3.86 0.25a Benign T2073A À3.84 0.28a Possibly damaging E815G À3.53 - Probably damaging R1615Q À3.45 - Possibly damaging S1181F À3.44 - Possibly damaging R306H À3.31 - Benign E1386Q À2.44 0.51 Benign S1376G À2.19 - Benign R1341T À2.09 - Possibly damaging D2243E À1.6 - Benign P248A À0.18 - Benign a Efflux value is 2 SDs or more below control levels of 0.52 6 0.07.
X
ABCA1 p.Trp590Ser 16429166:110:295
status: NEWX
ABCA1 p.Trp590Ser 16429166:110:305
status: NEW
PMID: 16183915
[PubMed]
Oram JF et al: "ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease."
No.
Sentence
Comment
158
One substitution mutation (W590S), however, severely reduces apolipoprotein-mediated lipid efflux without having much effect on apolipoprotein binding (73).
X
ABCA1 p.Trp590Ser 16183915:158:27
status: NEW414 Only one mutant (W590S) has been described that has near-normal apolipoprotein binding activity but defective lipid transport (73).
X
ABCA1 p.Trp590Ser 16183915:414:17
status: NEW159 One substitution mutation (W590S), however, severely reduces apolipoprotein-mediated lipid efflux without having much effect on apolipoprotein binding (73).
X
ABCA1 p.Trp590Ser 16183915:159:27
status: NEW413 Only one mutant (W590S) has been described that has near-normal apolipoprotein binding activity but defective lipid transport (73).
X
ABCA1 p.Trp590Ser 16183915:413:17
status: NEW
PMID: 15891392
[PubMed]
Van Eck M et al: "Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis."
No.
Sentence
Comment
33
However, Fitzgerald and colleagues [32 ] recently demonstrated that a mutant form of ABCA1 (W590S), which avidly binds apoA-I but fails to promote lipid efflux to apoA-I, released apoA-I with the same kinetics as wild-type ABCA1, indicating that release of apoA-I from ABCA1 is independent of lipid transfer.
X
ABCA1 p.Trp590Ser 15891392:33:94
status: NEW
No.
Sentence
Comment
90
Many mutations in patients with TD and FHA have been identified in ECD1 of ABCA1, and three mutations (R587W, W590S, Q597R) cluster amino acids 587 to 59746,48,72 (see Fig. 2).
X
ABCA1 p.Trp590Ser 16158173:90:110
status: NEW92 In contrast, the W590S mu- Fig. 2.
X
ABCA1 p.Trp590Ser 16158173:92:17
status: NEW95 Immunostaining with the antibody against ECD1 confirmed the proper orientation of W590S.
X
ABCA1 p.Trp590Ser 16158173:95:82
status: NEW96 However, the apoA-I-mediated release of cholesterol and choline phospholipids from cells expressing W590S was as low as that of the other two mutants and less than 10% of that in cells expressing the wild-type ABCA1.
X
ABCA1 p.Trp590Ser 16158173:96:100
status: NEW97 The W590S mutation does not have any apparent effect on ATP hydrolysis or the interaction between apoA-I and ABCA1.
X
ABCA1 p.Trp590Ser 16158173:97:4
status: NEW98 Analyses of W590S should facilitate our understanding of the mechanism of HDL formation.
X
ABCA1 p.Trp590Ser 16158173:98:12
status: NEW
PMID: 15262183
[PubMed]
Probst MC et al: "Screening for functional sequence variations and mutations in ABCA1."
No.
Sentence
Comment
187
A mutation in the same codon (W590S) has already been described in a Tangier patient previously analyzed in our laboratory [7].
X
ABCA1 p.Trp590Ser 15262183:187:30
status: NEW245 This is supported by the fact that a mutation in the same codon was shown to cause Tangier disease (W590S) [7], but since the patient is only heterozygous for W590L, it remains unclear what additional mutation in ABCA1 causes the patients analphalipoproteinemia.
X
ABCA1 p.Trp590Ser 15262183:245:100
status: NEW
No.
Sentence
Comment
154
A mutation of ABCA1 that causes Tangier disease (W590S) does not affect apoA-I binding or initial ATP binding/hydrolysis but results in a defect in lipid efflux (11, 31, 32).
X
ABCA1 p.Trp590Ser 14722086:154:49
status: NEW155 Because apoA-I failed to affect calpain degradation of ABCA1-W590S in HEK293 cells (10), additional signals following apoA-I binding to ABCA1 are speculated to be necessary for the subsequent inhibition of calpain degradation.
X
ABCA1 p.Trp590Ser 14722086:155:49
status: NEWX
ABCA1 p.Trp590Ser 14722086:155:61
status: NEW156 Because apoA-I failed to affect calpain degradation of ABCA1-W590S in HEK293 cells (10), additional signals following apoA-I binding to ABCA1 are speculated to be necessary for the subsequent inhibition of calpain degradation.
X
ABCA1 p.Trp590Ser 14722086:156:61
status: NEW
PMID: 15017358
[PubMed]
Zannis VI et al: "Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer."
No.
Sentence
Comment
228
Previous cross-linking studies of ABCA1 mutants associated with Tangier disease showed that, with the exception of one mutant, namely ABCA1 [W590S], all other ABCA1 mutants failed to cross-link or cross-linked poorly with apoA-I [59].
X
ABCA1 p.Trp590Ser 15017358:228:141
status: NEW229 Mutant apoA-I forms exhibited differences in binding to the wild-type ABCA1 and W590S mutant, indicating that the W590S mutation may have altered the environment in the binding site of ABCA1 [58.. ].
X
ABCA1 p.Trp590Ser 15017358:229:80
status: NEWX
ABCA1 p.Trp590Ser 15017358:229:114
status: NEW279 Previous studies showed that an ABCA1 mutant, ABCA1[W590S], which has defective lipid efflux and causes Tangier disease [59], cross-links more efficiently to apoA-I than does wild-type ABCA1 at 378C.
X
ABCA1 p.Trp590Ser 15017358:279:52
status: NEW280 Analysis of the dissociation of the complexes formed between apoA-I and ABCA1 showed that the rate of dissociation was similar for the wild-type ABCA1 and the ABCA1[W590S] mutant [63.
X
ABCA1 p.Trp590Ser 15017358:280:165
status: NEW282 However, the apoA-I released from wild-type ABCA1 was bound to lipids, whereas the apoA-I released from ABCA1[W590S] was lipid-free [63.
X
ABCA1 p.Trp590Ser 15017358:282:110
status: NEW291 It has been shown that wild-type and mutant forms of apoA-I cross-link with different efficiencies to wild-type ABCA1 and the W590S mutant, suggesting different environment in the active site of the wild-type and the mutant ABCA1 [58.. ].
X
ABCA1 p.Trp590Ser 15017358:291:126
status: NEW292 As a result of these differences, the wild-type apoA-I forms a complex with ABCA1[W590S] but is released lipid-free [63.
X
ABCA1 p.Trp590Ser 15017358:292:82
status: NEW
PMID: 14967052
[PubMed]
Chroni A et al: "Cross-linking and lipid efflux properties of apoA-I mutants suggest direct association between apoA-I helices and ABCA1."
No.
Sentence
Comment
5
The WT apoA-I, amino, carboxy and double deletion mutants of apoA-I showed differences in the cross-linking to WT ABCA1 and the mutant ABCA1[W590S].
X
ABCA1 p.Trp590Ser 14967052:5:141
status: NEW16 To further examine the structural domains of apoA-I that affect the apoA-I/ABCA1 interactions, we tested the effect of amino-terminal, carboxy-terminal, and internal deletion mutants, as well as point mutants in the central helices of apoA-I on ABCA1-mediated lipid efflux and on the ability of apoA-I to cross-link to ABCA1. Furthermore, we tested the ability of apoA-I mutants to associate with the ABCA1[W590S] mutant, which is defective in cholesterol efflux but cross-links to apoA-I (20).
X
ABCA1 p.Trp590Ser 14967052:16:407
status: NEW204 Effect of Amino-Terminal, Carboxy-Terminal, and Double Amino- and Carboxy-Terminal Deletions of ApoA-I on the Ability of ApoA-I to Cross-Link to the ABCA1[W590S] Mutant.
X
ABCA1 p.Trp590Ser 14967052:204:155
status: NEW205 To further explore the interaction of apoA-I with ABCA1, we tested the ability of various apoA-I mutants to associate with the ABCA1[W590S] mutant.
X
ABCA1 p.Trp590Ser 14967052:205:133
status: NEW207 For this purpose, we performed a direct cross-linking of iodinated WT and mutant forms of apoA-I (0.2 µM) to WT ABCA1 or the ABCA1[W590S] mutant in the presence or absence of 30-fold molar excess of the corresponding unlabeled apoA-I form as described in the Experimental Procedures.
X
ABCA1 p.Trp590Ser 14967052:207:136
status: NEW208 As shown in Figure 5A, the WT apoA-I, the amino-terminal, and the double amino- and carboxy-terminal deletion mutants of apoA-I cross-link to ABCA1[W590S] and the cross-linking is completely inhibited by 30-fold molar excess of unlabeled apoA-I.
X
ABCA1 p.Trp590Ser 14967052:208:148
status: NEW209 The carboxy-terminal deletion mutants apoA-I[∆(185-243)] and apoA-I[∆(220-243)] cross-link less efficiently to either WT ABCA1 or mutant ABCA1[W590S], and the cross-linking is partially competed by 30-fold molar excess of unlabeled apolipoprotein.
X
ABCA1 p.Trp590Ser 14967052:209:157
status: NEW210 The WT apoA-I and the apoA-I[∆(1-41)∆(185-243)] mutant have higher and equal ability, respectively, to cross-link to ABCA1[W590S] as compared to WT ABCA1.
X
ABCA1 p.Trp590Ser 14967052:210:137
status: NEW211 However, the amino-terminal deletion mutant apoA-I[∆(1-41)] and the carboxy-terminal deletion mutants apoA-I[∆(185-243)] and apoA-I[∆(220-243)] show 36-64% reduced cross-linking to ABCA1[W590S] (Figure 5B).
X
ABCA1 p.Trp590Ser 14967052:211:208
status: NEW212 The finding suggests subtle differences in the cross-linking of WT and mutant apoA-I forms to the ABCA1[W590S] mutant as compared to the cross-linking of the same apoA-I forms to the WT ABCA1.
X
ABCA1 p.Trp590Ser 14967052:212:104
status: NEW241 This model is supported by the observation that, with the exception of a single mutant ABCA1[W590S], all other natural mutants in the two extracellular loops of ABCA1 tested, which are defective in cholesterol efflux, cross-link inefficiently to ABCA1 (20).
X
ABCA1 p.Trp590Ser 14967052:241:93
status: NEW263 With FIGURE 5: Cross-linking of 125I-labeled WT and mutant forms of apoA-I to WT ABCA1 and ABCA1[W590S].
X
ABCA1 p.Trp590Ser 14967052:263:97
status: NEW264 HEK293 cells transfected with plasmids carrying the WT ABCA1 and ABCA1[W590S] mutant were incubated for 1 h at 37 °C with 0.2 µM 125I-labeled WT or the indicated mutant forms of apoA-I alone or in the presence of a 30-fold molar excess of the respective unlabeled apolipoproteins.
X
ABCA1 p.Trp590Ser 14967052:264:71
status: NEW270 The fmol of cross-linked WT or mutant forms of apoA-I per mg of cellular protein to WT ABCA1 and ABCA1[W590S] were calculated as described in the legend of the Figure 2D,E and are graphed to panel B.
X
ABCA1 p.Trp590Ser 14967052:270:103
status: NEW271 Panel B shows the total cross-linking of the indicated apoA-I forms to WT ABCA1 and the ABCA1[W590S] mutant.
X
ABCA1 p.Trp590Ser 14967052:271:94
status: NEW274 The % ratio of the cross-linking of each 125I-labeled apoA-I form to the ABCA1[W590S] mutant to the cross-linking of the same apoA-I form to the WT ABCA1 was also calculated and is shown in the lower part of the panel B.
X
ABCA1 p.Trp590Ser 14967052:274:79
status: NEW316 Interactions of WT and Mutant Forms of ApoA-I with the WT ABCA1 and the ABCA1[W590S] Mutant Differ and May Account for the Inability of the ABCA1[W590S] Mutant, Which Binds Strongly to ApoA-I, To Promote Cholesterol Efflux.
X
ABCA1 p.Trp590Ser 14967052:316:78
status: NEWX
ABCA1 p.Trp590Ser 14967052:316:146
status: NEW317 The present, as well as a previous study (20), showed that the ABCA1[W590S] cross-links better than WT ABCA1 to apoA-I but fails to promote cholesterol efflux in vitro and HDL formation in vivo (7, 20).
X
ABCA1 p.Trp590Ser 14967052:317:69
status: NEW318 However, as shown in this study, the amino- and carboxy-terminal deletion mutants cross-link less efficiently to the ABCA1[W590S] mutant, and the double deletion mutant cross-links with similar efficiency to the WT and the mutant ABCA1 forms.
X
ABCA1 p.Trp590Ser 14967052:318:123
status: NEW320 If the binding of apoA-I acceptors to the ABCA1 [W590S] mutant was brought about by ABCA1-dependent changes in the cell membrane (11, 12), one would expect that apoA-I mutants that bind inefficiently to the WT ABCA1 would also bind inefficiently to the ABCA1[W590S] mutant and vice versa.
X
ABCA1 p.Trp590Ser 14967052:320:49
status: NEWX
ABCA1 p.Trp590Ser 14967052:320:259
status: NEW321 One possible way then to interpret the inability of the ABCA1[W590S] mutant to promote cholesterol efflux, is to assume that the complex formed is a non-productive complex that prevents the lipidation of apoA-I that is bound to ABCA1.
X
ABCA1 p.Trp590Ser 14967052:321:62
status: NEW323 In fact, recent experiments have confirmed this hypothesis by showing that following binding to the WT ABCA1, the apoA-I is released associated with cholesterol, whereas apoA-I bound to the ABCA1[W590S] mutant is released in lipid-free form (49).
X
ABCA1 p.Trp590Ser 14967052:323:196
status: NEW333 In the case of the ABCA1[W590S] mutant, the complex is formed but the FIGURE 7: Two step model of cholesterol efflux.
X
ABCA1 p.Trp590Ser 14967052:333:25
status: NEW339 Formation of a non-productive complex is supported by our data, which showed that WT and mutant apoA-I have differences in their cross-linking to the WT ABCA1 and the ABCA1[W590S] mutant.
X
ABCA1 p.Trp590Ser 14967052:339:173
status: NEW
PMID: 14748729
[PubMed]
Knight BL et al: "ATP-binding cassette transporter A1: regulation of cholesterol efflux."
No.
Sentence
Comment
65
Furthermore, a specific mutation in the first loop (W590S) reduced efflux without affecting apoA1 binding, indicating that acceptor binding is necessary, but not sufficient, for cholesterol efflux.
X
ABCA1 p.Trp590Ser 14748729:65:52
status: NEW64 Furthermore, a specific mutation in the first loop (W590S) reduced efflux without affecting apoA1 binding, indicating that acceptor binding is necessary, but not sufficient, for cholesterol efflux.
X
ABCA1 p.Trp590Ser 14748729:64:52
status: NEW
PMID: 14617740
[PubMed]
Fitzgerald ML et al: "ABCA1 and amphipathic apolipoproteins form high-affinity molecular complexes required for cholesterol efflux."
No.
Sentence
Comment
7
A mutant form of ABCA1 (W590S) that avidly binds apoA-I but fails to promote cholesterol efflux released apoA-I with similar kinetics but without transfer of cholesterol to apoA-I.
X
ABCA1 p.Trp590Ser 14617740:7:24
status: NEW127 Previously, we had demonstrated that a mutant form of ABCA1, containing a missense mutation resulting in the substitution of serine for tryptophan at amino acid position 590, produced a transporter that had greater apoA-I cross-linking activity than wild-type ABCA1.
X
ABCA1 p.Trp590Ser 14617740:127:125
status: NEW129 This mutant (W590S) retains the temperature dependence of cross-linking we previously demonstrated for wild-type ABCA1 (Fig. 4A), suggesting that its binding interaction Fig. 2.
X
ABCA1 p.Trp590Ser 14617740:129:13
status: NEW141 Thus, the dissociation of apoA-I from both wild-type ABCA1 and ABCA1(W590S) was tested.
X
ABCA1 p.Trp590Ser 14617740:141:28
status: NEWX
ABCA1 p.Trp590Ser 14617740:141:69
status: NEW142 Cells expressing ABCA1, the W590S mutant, or no ABCA1 (mock) were exposed to 125I-apoA-I at 37ЊC for 1 h.
X
ABCA1 p.Trp590Ser 14617740:142:28
status: NEW147 Fig. 4B (top panels) shows the amount of 125I-apoA-I associated with wild-type ABCA1 or the W590S mutant as assessed by the cross-linking assay.
X
ABCA1 p.Trp590Ser 14617740:147:13
status: NEWX
ABCA1 p.Trp590Ser 14617740:147:92
status: NEW148 Although the W590S mutant was found to be associated with substantially more radiolabeled apoA-I at time zero, its dissociation rate from the apolipoprotein (half-life of 30.1 min) did not differ markedly from that measured for the wild-type transporter (half-life of 24.6 min) (Fig. 4B, graph).
X
ABCA1 p.Trp590Ser 14617740:148:13
status: NEW153 Cells expressing the W590S mutant also released the apoA-I back into the medium at a similar rate.
X
ABCA1 p.Trp590Ser 14617740:153:21
status: NEWX
ABCA1 p.Trp590Ser 14617740:153:143
status: NEW154 These results, along with the measurements of the kinetics of dissociation described above, indicate that the cholesterol efflux defect in the W590S mutant cannot be accounted for by either a failure of the apoA-I/ABCA1 complex to dissociate or an ectopic release of apoA-I.
X
ABCA1 p.Trp590Ser 14617740:154:143
status: NEW156 The apoA-I released from the cells expressing the W590S mutant migrated at the expected molecular weight of lipid-depleted, monomeric apoA-I (Fig. 4D).
X
ABCA1 p.Trp590Ser 14617740:156:50
status: NEW170 IP, immunoprecipitant. wild-type ABCA1 had acquired lipid, whereas the apoA-I released from cells expressing the W590S mutant had not.
X
ABCA1 p.Trp590Ser 14617740:170:115
status: NEW173 Cells that were either mock-transfected or that expressed the W590S mutant had similarly low levels of [14C]cholesterol associated with apoA-I in the medium (Fig. 4D, graph).
X
ABCA1 p.Trp590Ser 14617740:173:7
status: NEWX
ABCA1 p.Trp590Ser 14617740:173:62
status: NEW174 As the W590S mutant had a similar impairment in its ability to transfer phosphatidylcholine to apoA-I (data not shown), the mutant does not provide a tool for dissociating the mechanisms of efflux of these two lipids.
X
ABCA1 p.Trp590Ser 14617740:174:7
status: NEW176 ApoA-I associates with the ABCA1 W590S mutant in a temperature-dependent manner and is released from the mutant complex with kinetics similar to the release from wild-type ABCA1 (wtABCA1).
X
ABCA1 p.Trp590Ser 14617740:176:17
status: NEWX
ABCA1 p.Trp590Ser 14617740:176:33
status: NEW177 A: ABCA1 and the W590S mutant display a similar temperature sensitivity of complex formation.
X
ABCA1 p.Trp590Ser 14617740:177:17
status: NEW178 Wild-type ABCA1, the W590S mutant, or empty vector (mock)-expressing cells were incubated with 125I-apoA-I at either 37ЊC or 4ЊC for 1 h.
X
ABCA1 p.Trp590Ser 14617740:178:21
status: NEW182 B: ApoA-I complexes between wild-type ABCA1 and the W590S mutant turn over at a similar rate.
X
ABCA1 p.Trp590Ser 14617740:182:30
status: NEWX
ABCA1 p.Trp590Ser 14617740:182:52
status: NEW183 Cells expressing ABCA1 or the W590S mutant were incubated with 125I-apoA-I at 37ЊC for 1 h and then washed with warm PBS.
X
ABCA1 p.Trp590Ser 14617740:183:30
status: NEW186 C: ABCA1 and the W590S mutant cells release cell-associated apoA-I with similar kinetics.
X
ABCA1 p.Trp590Ser 14617740:186:17
status: NEW188 Graphed is the amount of 125I-apoA-I released from wild-type ABCA1 and W590S-expressing cells relative to the mock cells (duplicate samples, ϮSD) D: Only apoA-I released from wild-type ABCA1 is associated with cholesterol.
X
ABCA1 p.Trp590Ser 14617740:188:71
status: NEW223 In our studies, we compared the dissociation behavior of wild-type ABCA1/apoA-I complexes with those formed with the W590S ABCA1 mutant.
X
ABCA1 p.Trp590Ser 14617740:223:117
status: NEW225 The W590S mutant, like wild-type ABCA1, was not able to form a cross-linkable complex with apoA-I at 4ЊC.
X
ABCA1 p.Trp590Ser 14617740:225:4
status: NEWX
ABCA1 p.Trp590Ser 14617740:225:37
status: NEW226 At 37ЊC, apoA-I dissociated from the W590S mutant at a rate similar to that measured using the wild-type ABCA1 (half-life of 30 versus 25 min, respectively).
X
ABCA1 p.Trp590Ser 14617740:226:43
status: NEW228 These results suggest that the W590S mutant binds and releases apoA-I in a normal manner but that these processes are uncoupled from the transfer of cholesterol to the released apoA-I.
X
ABCA1 p.Trp590Ser 14617740:228:30
status: NEW229 Our results indicate that the W590S mutant has a similar impairment in the transfer of phospholipid, and as reported by Rigot et al. (9), the mutant does not stimulate the translocation of phosphatidylserine to the outer leaflet of the plasma membrane.
X
ABCA1 p.Trp590Ser 14617740:229:30
status: NEW231 If this mechanism were operative, it seems unlikely that the apoA-I would dissociate from the W590S mutant with the kinetics we have measured.
X
ABCA1 p.Trp590Ser 14617740:231:20
status: NEWX
ABCA1 p.Trp590Ser 14617740:231:96
status: NEW232 The behavior of the W590S mutant/apoA-I complex indicates that the cellular release of apoA-I and the transfer of cholesterol and phospholipid are separable events and thus likely distinct steps in the efflux mechanism.
X
ABCA1 p.Trp590Ser 14617740:232:20
status: NEW242 The W590S ABCA1 mutant demonstrates that this release is not dependent on cholesterol transfer to the acceptor apolipoprotein, indicating that release and cholesterol transfer are separable events in the efflux process.
X
ABCA1 p.Trp590Ser 14617740:242:4
status: NEW6 A mutant form of ABCA1 (W590S) that avidly binds apoA-I but fails to promote cholesterol efflux released apoA-I with similar kinetics but without transfer of cholesterol to apoA-I.
X
ABCA1 p.Trp590Ser 14617740:6:24
status: NEW126 Previously, we had demonstrated that a mutant form of ABCA1, containing a missense mutation resulting in the substitution of serine for tryptophan at amino acid position 590, produced a transporter that had greater apoA-I cross-linking activity than wild-type ABCA1.
X
ABCA1 p.Trp590Ser 14617740:126:125
status: NEW128 This mutant (W590S) retains the temperature dependence of cross-linking we previously demonstrated for wild-type ABCA1 (Fig. 4A), suggesting that its binding interaction Fig. 2.
X
ABCA1 p.Trp590Ser 14617740:128:13
status: NEW140 Thus, the dissociation of apoA-I from both wild-type ABCA1 and ABCA1(W590S) was tested.
X
ABCA1 p.Trp590Ser 14617740:140:69
status: NEW146 Fig. 4B (top panels) shows the amount of 125I-apoA-I associated with wild-type ABCA1 or the W590S mutant as assessed by the cross-linking assay.
X
ABCA1 p.Trp590Ser 14617740:146:92
status: NEW152 Cells expressing the W590S mutant also released the apoA-I back into the medium at a similar rate.
X
ABCA1 p.Trp590Ser 14617740:152:21
status: NEW155 The apoA-I released from the cells expressing the W590S mutant migrated at the expected molecular weight of lipid-depleted, monomeric apoA-I (Fig. 4D).
X
ABCA1 p.Trp590Ser 14617740:155:50
status: NEW169 IP, immunoprecipitant. wild-type ABCA1 had acquired lipid, whereas the apoA-I released from cells expressing the W590S mutant had not.
X
ABCA1 p.Trp590Ser 14617740:169:115
status: NEW172 Cells that were either mock-transfected or that expressed the W590S mutant had similarly low levels of [14C]cholesterol associated with apoA-I in the medium (Fig. 4D, graph).
X
ABCA1 p.Trp590Ser 14617740:172:62
status: NEW175 ApoA-I associates with the ABCA1 W590S mutant in a temperature-dependent manner and is released from the mutant complex with kinetics similar to the release from wild-type ABCA1 (wtABCA1).
X
ABCA1 p.Trp590Ser 14617740:175:33
status: NEW181 B: ApoA-I complexes between wild-type ABCA1 and the W590S mutant turn over at a similar rate.
X
ABCA1 p.Trp590Ser 14617740:181:52
status: NEW185 C: ABCA1 and the W590S mutant cells release cell-associated apoA-I with similar kinetics.
X
ABCA1 p.Trp590Ser 14617740:185:17
status: NEW187 Graphed is the amount of 125I-apoA-I released from wild-type ABCA1 and W590S-expressing cells relative to the mock cells (duplicate samples, SD) D: Only apoA-I released from wild-type ABCA1 is associated with cholesterol.
X
ABCA1 p.Trp590Ser 14617740:187:71
status: NEW222 In our studies, we compared the dissociation behavior of wild-type ABCA1/apoA-I complexes with those formed with the W590S ABCA1 mutant.
X
ABCA1 p.Trp590Ser 14617740:222:117
status: NEW224 The W590S mutant, like wild-type ABCA1, was not able to form a cross-linkable complex with apoA-I at 4C.
X
ABCA1 p.Trp590Ser 14617740:224:4
status: NEW227 These results suggest that the W590S mutant binds and releases apoA-I in a normal manner but that these processes are uncoupled from the transfer of cholesterol to the released apoA-I.
X
ABCA1 p.Trp590Ser 14617740:227:31
status: NEW230 If this mechanism were operative, it seems unlikely that the apoA-I would dissociate from the W590S mutant with the kinetics we have measured.
X
ABCA1 p.Trp590Ser 14617740:230:96
status: NEW241 The W590S ABCA1 mutant demonstrates that this release is not dependent on cholesterol transfer to the acceptor apolipoprotein, indicating that release and cholesterol transfer are separable events in the efflux process.
X
ABCA1 p.Trp590Ser 14617740:241:4
status: NEW
PMID: 14592415
[PubMed]
Ikeda Y et al: "Posttranscriptional regulation of human ABCA7 and its function for the apoA-I-dependent lipid release."
No.
Sentence
Comment
15
In fact, the three different mutants in ECD1 associated with TD, R587W, W590S, and Q597R, all had reduced apoA-I-mediated lipid release and subsequent HDL assembly when expressed in HEK293 [12-14].
X
ABCA1 p.Trp590Ser 14592415:15:72
status: NEW
PMID: 12869555
[PubMed]
Martinez LO et al: "Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I."
No.
Sentence
Comment
165
A mutant (ABCA1-W590S) showed normal levels of binding of apoA-I but decreased phospholipid efflux (22, 23).
X
ABCA1 p.Trp590Ser 12869555:165:16
status: NEW162 A mutant (ABCA1-W590S) showed normal levels of binding of apoA-I but decreased phospholipid efflux (22, 23).
X
ABCA1 p.Trp590Ser 12869555:162:16
status: NEW
PMID: 12763760
[PubMed]
Singaraja RR et al: "Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene."
No.
Sentence
Comment
76
Additional insights into how the mutations R587W, W590S, and Q597R that occur in the extracellular loops affect ABCA1 function have recently been described.58-60 Two studies have reported that ABCA1 containing the point mutation Q597R, which occurs in the first extracellular loop, does not localize to the plasma membrane.59,60 However, other studies have reported that this mutant is expressed at the plasma membrane but at reduced levels relative to wild-type ABCA1.58,44 R587W, another missense mutation in the first extracellular loop, also prevents the trafficking of ABCA1 to the plasma membrane, although results with this mutant have been variable.58-60 Both the R587W and Q597R mutants are resistant to PNGase digestion, indicating that they are not glycosylated, suggesting that ABCA1 harboring these mutations does not traverse the medial and trans Golgi network.
X
ABCA1 p.Trp590Ser 12763760:76:50
status: NEW78 ABCA1 harboring the W590S mutation does reach the cell surface, and cross-linking studies reported normal interaction of the W590S mutant with ApoA-I despite defective efflux, suggesting that interaction with ApoA-I may not be sufficient for lipid efflux.58 ABCA1 that does not reach the plasma membrane cannot induce the binding of ApoA-I.
X
ABCA1 p.Trp590Ser 12763760:78:20
status: NEWX
ABCA1 p.Trp590Ser 12763760:78:125
status: NEW83 TABLE 2. Conservation of Amino Acid Residues Mutated in Humans Mutation H. sapiens M. musculus G. gallus D. melanogaster C. elegans P85L P P P ⅐ ⅐ ⅐ P R230C R R R P G A255T A A S ⅐ ⅐ ⅐ ⅐ ⅐ ⅐ R587W R R R ⅐ ⅐ ⅐ ⅐ ⅐ ⅐ W590S W W W R Q Q597R Q Q Q Q Q ⌬L693 L L L L L T929I T T T T T N935S/H N N N N N A937V A A A A A A1046D A A A A A M1091T M M M M M D1099Y D D D D D D1289L/N D D D D D C1477R C C C ⅐ ⅐ ⅐ ⅐ ⅐ ⅐ S1506L S S S ⅐ ⅐ ⅐ ⅐ ⅐ ⅐ N1611D N N N N S R1680W R R R R R N1800H N N N A W F2009S F F F I M R2081W R R R R R P2150L P P P R N ⌬E1893 E E E D S ⌬D1894 D D D D D Twenty-three of 24 (95.83%) amino acids affected by mutations are conserved with G. gallus, reflecting the functional importance of these residues.
X
ABCA1 p.Trp590Ser 12763760:83:320
status: NEW114 Patients homozygous for the mutations A255T and R1680W show HDL-C levels that are greater than 10% of age-and sex-matched population controls.
X
ABCA1 p.Trp590Ser 12763760:114:76
status: NEW122 This is indeed the case in heterozygous patients harboring mutations A255T, W590S, T929I, R1680W, and A937V, who all show HDL-C levelsϾ75% of normal age-and sex-matched controls.
X
ABCA1 p.Trp590Ser 12763760:122:76
status: NEW68 Additional insights into how the mutations R587W, W590S, and Q597R that occur in the extracellular loops affect ABCA1 function have recently been described.58-60 Two studies have reported that ABCA1 containing the point mutation Q597R, which occurs in the first extracellular loop, does not localize to the plasma membrane.59,60 However, other studies have reported that this mutant is expressed at the plasma membrane but at reduced levels relative to wild-type ABCA1.58,44 R587W, another missense mutation in the first extracellular loop, also prevents the trafficking of ABCA1 to the plasma membrane, although results with this mutant have been variable.58-60 Both the R587W and Q597R mutants are resistant to PNGase digestion, indicating that they are not glycosylated, suggesting that ABCA1 harboring these mutations does not traverse the medial and trans Golgi network.
X
ABCA1 p.Trp590Ser 12763760:68:50
status: NEW70 ABCA1 harboring the W590S mutation does reach the cell surface, and cross-linking studies reported normal interaction of the W590S mutant with ApoA-I despite defective efflux, suggesting that interaction with ApoA-I may not be sufficient for lipid efflux.58 ABCA1 that does not reach the plasma membrane cannot induce the binding of ApoA-I.
X
ABCA1 p.Trp590Ser 12763760:70:20
status: NEWX
ABCA1 p.Trp590Ser 12763760:70:125
status: NEW75 TABLE 2. Conservation of Amino Acid Residues Mutated in Humans Mutation H. sapiens M. musculus G. gallus D. melanogaster C. elegans P85L P P P ዼ ዼ ዼ P R230C R R R P G A255T A A S ዼ ዼ ዼ ዼ ዼ ዼ R587W R R R ዼ ዼ ዼ ዼ ዼ ዼ W590S W W W R Q Q597R Q Q Q Q Q èc;L693 L L L L L T929I T T T T T N935S/H N N N N N A937V A A A A A A1046D A A A A A M1091T M M M M M D1099Y D D D D D D1289L/N D D D D D C1477R C C C ዼ ዼ ዼ ዼ ዼ ዼ S1506L S S S ዼ ዼ ዼ ዼ ዼ ዼ N1611D N N N N S R1680W R R R R R N1800H N N N A W F2009S F F F I M R2081W R R R R R P2150L P P P R N èc;E1893 E E E D S èc;D1894 D D D D D Twenty-three of 24 (95.83%) amino acids affected by mutations are conserved with G. gallus, reflecting the functional importance of these residues.
X
ABCA1 p.Trp590Ser 12763760:75:305
status: NEW
PMID: 12738681
[PubMed]
Wang N et al: "Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux."
No.
Sentence
Comment
46
Importantly, many ABCA1 missense mutations causing Tangier disease have been identified in these loops.29 A functional test of these mutations in transfected cells revealed defects in apoA-I binding and cellular lipid efflux.27,28 Interestingly, one of the mutants, W590S, showed lipid efflux deficiency but moder- Figure 1.
X
ABCA1 p.Trp590Ser 12738681:46:266
status: NEWX
ABCA1 p.Trp590Ser 12738681:46:296
status: NEW51 Together, these results also suggest that apoA-I binding requires an ABCA1 molecule assuming an optimal structural conformation that is maintained by a functional ATPase because cell-surface ABCA1 mutants with defective ATPase fail to bind apoA-I.23,32 The moderate increase in apoA-I binding to W590S may imply that dissociation of apoA-I from ABCA1 could be facilitated by lipid efflux to apolipoproteins bound to ABCA1 and is consistent with the earlier finding that ABCA1 binds apoA-I but not HDL3.7 Extrahepatic ABCA1 functions to promote cholesterol efflux from peripheral tissues to lipid-poor apolipoproteins that in turn deliver the lipid load back to liver for disposal, a process likely involving scavenger receptor BI, which has high affinity for lipid-rich HDLs but low affinity for lipid-poor apolipoproteins.33 Hepatic ABCA1 is likely involved in pre-beta HDL formation in liver, demonstrated by increased pre-beta HDL as well as more mature HDL levels in mice with adenovirus-mediated expression of ABCA1.34 Like scavenger receptor BI, ABCA1 binds not only apoA-I but also other apolipoproteins, including apoE.35 Thus, the antiatherogenic effect of apoE in vivo could be partially explained by lipid efflux from macrophage foam cells coordinated with ABCA1.
X
ABCA1 p.Trp590Ser 12738681:51:296
status: NEW78 It may also cause conformational changes of ABCA1, as reported for ligand-induced conformational changes of other ABC transporters.48 Cholesterol efflux appears to have no effect on ABCA1 protein levels because HDL and cyclodextrin treatment promoted cholesterol efflux to an extent similar to or greater than that by apoA-I-mediated cholesterol efflux but failed to alter ABCA1 protein levels.31 Another mutation of ABCA1 that causes Tangier disease (W590S) has been shown to cause a moderate increase in apoA-I binding but defective lipid efflux.27 ApoA-I failed to increase ABCA1-W590S levels whereas calpeptin significantly increased ABCA1-W590S proteins, suggesting that apoA-I binding is not sufficient for ABCA1 stabilization.31 These results favor the hypothesis that apoA-I-mediated ABCA1 stabilization may result from a local change in membrane phospholipids that decreases the binding of a hydrophobic, glycine-rich sequence of the small calpain subunit.49 However, an equally valid interpretation is that apoA-I fails to bind the W590S mutant in the correct orientation and therefore the appropriate conformational change of ABCA1 required to decrease calpain proteolysis does not occur.
X
ABCA1 p.Trp590Ser 12738681:78:452
status: NEWX
ABCA1 p.Trp590Ser 12738681:78:583
status: NEWX
ABCA1 p.Trp590Ser 12738681:78:644
status: NEWX
ABCA1 p.Trp590Ser 12738681:78:1042
status: NEW41 Importantly, many ABCA1 missense mutations causing Tangier disease have been identified in these loops.29 A functional test of these mutations in transfected cells revealed defects in apoA-I binding and cellular lipid efflux.27,28 Interestingly, one of the mutants, W590S, showed lipid efflux deficiency but moder- Figure 1.
X
ABCA1 p.Trp590Ser 12738681:41:266
status: NEW73 It may also cause conformational changes of ABCA1, as reported for ligand-induced conformational changes of other ABC transporters.48 Cholesterol efflux appears to have no effect on ABCA1 protein levels because HDL and cyclodextrin treatment promoted cholesterol efflux to an extent similar to or greater than that by apoA-I-mediated cholesterol efflux but failed to alter ABCA1 protein levels.31 Another mutation of ABCA1 that causes Tangier disease (W590S) has been shown to cause a moderate increase in apoA-I binding but defective lipid efflux.27 ApoA-I failed to increase ABCA1-W590S levels whereas calpeptin significantly increased ABCA1-W590S proteins, suggesting that apoA-I binding is not sufficient for ABCA1 stabilization.31 These results favor the hypothesis that apoA-I-mediated ABCA1 stabilization may result from a local change in membrane phospholipids that decreases the binding of a hydrophobic, glycine-rich sequence of the small calpain subunit.49 However, an equally valid interpretation is that apoA-I fails to bind the W590S mutant in the correct orientation and therefore the appropriate conformational change of ABCA1 required to decrease calpain proteolysis does not occur.
X
ABCA1 p.Trp590Ser 12738681:73:452
status: NEWX
ABCA1 p.Trp590Ser 12738681:73:583
status: NEWX
ABCA1 p.Trp590Ser 12738681:73:644
status: NEWX
ABCA1 p.Trp590Ser 12738681:73:1042
status: NEW
No.
Sentence
Comment
66
TD 1591 T/C 11 V399A extracellular [68] TD 1979 (110bpAlu Ins) 12 truncated truncation [60] TD/FHA 2154 C/T 14 R587W extracellular [67,69] TD 2164 G/C 14 W590S extracellular [61] TD 2185 A/G 14 Q597R extracellular [59,67] TD 2219 G/del 14 truncated, 635X truncated [60,61] FHA 2472-2474 3bp del 15 Del L693 TM domain #3 [59] phosphorylation 2706 G/A 16 V771M extracellular [68] 2715 A/C 16 T774P extracellular [68] 2723 G/C 16 K776N extracellular [68] 2868 G/A 17 V825I TM domain #6 [67,68] TD/FHA 3044 A/G 18 I883M cytoplasmic [68] phosphorylat site FHA 3120 C/T 19 R909X truncation [63,71] TD 3181 C/T 19 T929I cytoplasmic [62] TD 3199 A/G 19 N935S Walker A [61] TD 3205 C/T 19 A937V Walker A [61] TD 3532 C/A 22 A1046D cytoplasmic, Walker A/B [70] FHA 3667 T/C 23 M1091T cytoplasmic [63] 3690 G/T 23 D1099Y cytoplasmic [9] TD 3738 2bp del 23 1145X truncation [66] FHA 3911 G/C 24 E1172D linker/cytoplasmic [68] FHA 4242 4bp del 27 1297X truncated [64] TD 4260 G/A 27 D1289N linker cytoplasm [64,65] TD 4824 T/C 31 C1477R extracellular [59] TD 4912 C/T 32 S1506L extracellular loop #2 [71] TD 5025 ins A 34 A1544S?1552X truncation [70] 5059 T/C 34 I1555T extracellular loop #2 [67] 5155 G/A 35 R1587K extracellular loop #2 [68] FHA 5226 A/G 36 N1611D extracellular loop #2 [75..] 5338 T/C 36 L1648P extracellular loop #2 [67] TD 5443 C/T 37 R1680W cytoplasmic [74.]
X
ABCA1 p.Trp590Ser 12840658:66:154
status: NEW
PMID: 12509412
[PubMed]
Tanaka AR et al: "Effects of mutations of ABCA1 in the first extracellular domain on subcellular trafficking and ATP binding/hydrolysis."
No.
Sentence
Comment
1
The three different mutants in the first extracellular domain of human ABCA1 associated with Tangier disease, R587W, W590S, and Q597R, were examined for their subcellular localization and function by using ABCA1-GFP fusion protein stably expressed in HEK293 cells.
X
ABCA1 p.Trp590Ser 12509412:1:117
status: NEW5 R587W and Q597R were associated with impaired processing of oligosaccharide from high mannose type to complex type and failed to be localized to the PM, whereas W590S did not show such dysfunctions.
X
ABCA1 p.Trp590Ser 12509412:5:161
status: NEW6 Vanadate-induced nucleotide trapping was examined to elucidate the mechanism for the dysfunction in the W590S mutant.
X
ABCA1 p.Trp590Ser 12509412:6:104
status: NEW7 Photoaffinity labeling of W590S with 8-azido-[␣- 32 P]ATP was stimulated by adding ortho-vanadate in the presence of Mn2؉ as much as in the presence of wild-type ABCA1.
X
ABCA1 p.Trp590Ser 12509412:7:26
status: NEW8 These results suggest that the defect of HDL assembly in R587W and Q597R is due to the impaired localization to the PM, whereas W590S has a functional defect other than the initial ATP binding and hydrolysis.
X
ABCA1 p.Trp590Ser 12509412:8:128
status: NEW20 Three TD mutants (R587W, W590S, Q597R), clustered in ECD1, were examined in the present report.
X
ABCA1 p.Trp590Ser 12509412:20:25
status: NEW24 On the other hand, the two mutants R587W and Q597R were only partially or scarcely localized to the PM, whereas W590S * This work was supported by Grant-in-aid for Scientific Research 10217205 on Priority Areas "ABC Proteins" from the Ministry of Education, Science, Sports, and Culture of Japan and by the Nakajima Foundation.
X
ABCA1 p.Trp590Ser 12509412:24:112
status: NEW35 Vanadate-induced nucleotide trapping was examined to elucidate the mechanism for the dysfunction in the W590S mutant.
X
ABCA1 p.Trp590Ser 12509412:35:104
status: NEW44 DNA Construction-DNA fragments (XhoI-BclI) containing each missense TD mutation (R587W, W590S, or Q597R) were generated using the polymerase chain reaction method with R587W (XhoI) primer (5Ј-GTCCTCGAGCTGACCCCTTTGAGGACATGTGGTACGTC-3Ј), W590S (XhoI) primer (5Ј-GTCCTCGAGCTGACCCCTTTGAGGACAT- GCGGTACGTCTCGGGGGGCTTC-3Ј), or Q597 (XhoI) primer (5Ј-GT- CCTCGAGCTGACCCCTTTGAGGACATGCGGTACGTCTGGGGGGG- CTTCGCCTACTTGCGGGATGTGGTG-3Ј), where the mutated nucleotide is underlined, and BclI primer (5Ј-CGATGCCCTTGATGATCACA- GCCACTGAG-3Ј).
X
ABCA1 p.Trp590Ser 12509412:44:88
status: NEWX
ABCA1 p.Trp590Ser 12509412:44:248
status: NEW47 In brief, 10 g of membrane proteins from HEK293 cells stably expressing the wild-type, R587W, W590S, or Q597R ABCA1-GFP were treated with 500 units of Endo H or 0.3 units of PNGaseF for 1 h at 37 °C.
X
ABCA1 p.Trp590Ser 12509412:47:101
status: NEW53 Vanadate-induced Nucleotide Trapping in ABCA1 with 8-Azido-[␣- 32 P]ATP-A membrane fraction (20-30 g) was prepared from HEK293 cells stably expressing the wild-type or W590S ABCA1-GFP.
X
ABCA1 p.Trp590Ser 12509412:53:181
status: NEW64 Effects of ECD1 Mutations on Subcellular Localization of ABCA1-GFP-Many mutations in patients with TD and FHA have been identified in ECD1 of ABCA1, and three mutations (R587W, W590S, Q597R) cluster in the vicinity between amino acids 587 and 597 (20)(Fig. 2A).
X
ABCA1 p.Trp590Ser 12509412:64:177
status: NEW68 Confocal microscopic examination revealed that R587W and Q597R appeared to be localized mainly in the ER and not to the PM (Fig. 2B).
X
ABCA1 p.Trp590Ser 12509412:68:13
status: NEW69 In contrast, W590S was localized to the PM as much as the wild-type ABCA1-GFP was, although more was found with intracellular vesicles than with the wild type (Fig. 2B).
X
ABCA1 p.Trp590Ser 12509412:69:13
status: NEWX
ABCA1 p.Trp590Ser 12509412:69:82
status: NEW70 Immunostaining with the antibody against ECD1 confirmed the proper orientation of W590S (Fig. 2C).
X
ABCA1 p.Trp590Ser 12509412:70:82
status: NEWX
ABCA1 p.Trp590Ser 12509412:70:91
status: NEW71 Glycosylation of ABCA1-GFP-Glycosylation of the wild-type ABCA1-GFP and its mutants R587W, W590S, and Q597R was examined by the treatment with PNGaseF and Endo H (Fig. 3A).
X
ABCA1 p.Trp590Ser 12509412:71:91
status: NEW75 These results indicated that R587W and Q597R ABCA1-GFP did not contain complex oligosaccharides and supported the confocal microscopy observation, which suggested the localization of these two TD mutants in the ER or the cis-Golgi complex.
X
ABCA1 p.Trp590Ser 12509412:75:19
status: NEW76 On the other hand, W590S ABCA1-GFP was resistant to Endo H, indicating that it does not contain high mannose oligosaccharides but contains complex oligosaccharides and reached the trans-Golgi complex.
X
ABCA1 p.Trp590Ser 12509412:76:19
status: NEW87 The apoA-I-mediated release of cholesterol and choline-phospholipids from HEK293 expressing W590S ABCA1-GFP were 7.4 and 13%, respectively, of those expressing the wild-type ABCA1-GFP, although W590S ABCA1-GFP was localized to the PM as efficiently as the wild type.
X
ABCA1 p.Trp590Ser 12509412:87:92
status: NEWX
ABCA1 p.Trp590Ser 12509412:87:194
status: NEW89 The results were similar to those observed with the stable transformants shown in Fig. 4, A and B. Interaction of ABCA1-GFP with 8-Azido-[␣-32 P]ATP-To elucidate the mechanism for the loss of function of ABCA1 in the W590S mutant, we examined the interaction of ABCA1-GFP with ATP.
X
ABCA1 p.Trp590Ser 12509412:89:224
status: NEW102 A, a putative secondary structure of ABCA1 and localization of Tangier Disease mutations R587W, W590S, and Q597R in ECD1.
X
ABCA1 p.Trp590Ser 12509412:102:96
status: NEWX
ABCA1 p.Trp590Ser 12509412:102:111
status: NEW103 B, GFP fluorescence of HEK293 cells stably expressing the wild-type (WT) ABCA1-GFP and three TD mutants R587W, W590S, and Q597R ABCA1-GFP.
X
ABCA1 p.Trp590Ser 12509412:103:36
status: NEWX
ABCA1 p.Trp590Ser 12509412:103:111
status: NEW104 C, immunofluorescent observation of W590S ABCA1-GFP with anti-ECD1 antibody and anti-rat IgG-Alexa594.
X
ABCA1 p.Trp590Ser 12509412:104:36
status: NEW107 The wild-type (WT), R587W, W590S, and Q597R ABCA1-GFP were treated with none (-), Endo H (H), or PNGaseF (F) and separated with 7% SDS-PAGE.
X
ABCA1 p.Trp590Ser 12509412:107:27
status: NEW111 Cholesterol (A) and choline-phospholipid (B) content in the medium in a 6-well plate containing HEK293 cells stably expressing the wild-type (WT), R587W (RW), W590S (WS), and Q597R (QR) ABCA1-GFP were measured after a 24-h incubation in the presence (black bars) or absence (white bars) of 10 g/ml apoA-I. The relative amount of cholesterol (C) and choline-phospholipid (D) in the medium in a 6-well plate containing HEK293 cells transiently expressing the wild-type (WT), R587W (RW), W590S (WS), and Q597R (QR) ABCA1-GFP was measured after a 24-h incubation in the presence of 10 g/ml apoA-I. The expression levels of mutants were normalized with the GFP fluorescence of cells.
X
ABCA1 p.Trp590Ser 12509412:111:159
status: NEWX
ABCA1 p.Trp590Ser 12509412:111:493
status: NEW113 To determine whether the W590S mutation affects the ATP hydrolysis cycle of ABCA1, vanadate-induced nucleotide trapping in W590S ABCA1-GFP was examined in the presence of Mn2ϩ (Fig. 5C).
X
ABCA1 p.Trp590Ser 12509412:113:25
status: NEWX
ABCA1 p.Trp590Ser 12509412:113:86
status: NEWX
ABCA1 p.Trp590Ser 12509412:113:123
status: NEW114 Membrane proteins from HEK293 cells expressing a similar amount of wild-type ABCA1 or W590S ABCA1-GFP (Fig. 5B) were incubated with 8-azido-[␣-32 P]ATP in the absence or presence of ortho-vanadate.
X
ABCA1 p.Trp590Ser 12509412:114:30
status: NEWX
ABCA1 p.Trp590Ser 12509412:114:86
status: NEW115 The photoaffinity labeling of W590S ABCA1-GFP was stimulated by adding ortho-vanadate in the presence of Mn2ϩ as much as in the presence of the wild type.
X
ABCA1 p.Trp590Ser 12509412:115:30
status: NEW119 ABCA1-GFP with a R587W or Q597R mutation appeared to be impaired with intracellular trafficking and predominantly localized in the ER.
X
ABCA1 p.Trp590Ser 12509412:119:19
status: NEW120 On the other hand, W590S ABCA1-GFP was mainly localized to the PM as much as the wild-type ABCA1 was.
X
ABCA1 p.Trp590Ser 12509412:120:19
status: NEW122 R587W and Q597 ABCA1-GFP contained high mannose oligosaccharides, indicating that they do not reach the trans-Golgi complex.
X
ABCA1 p.Trp590Ser 12509412:122:13
status: NEW123 In contrast, W590S ABCA1-GFP contained complex-type oligosaccharides as the wild-type does.
X
ABCA1 p.Trp590Ser 12509412:123:13
status: NEW127 This region (R587 to Q597) in ECD1 would be critical for proper folding of ABCA1 and would probably affect the intracellular translocation process, whereas the W590S mutation does not.
X
ABCA1 p.Trp590Ser 12509412:127:160
status: NEW130 W590S ABCA1-GFP was localized to the PM as much as the wild-type ABCA1-GFP when expressed in HEK293.
X
ABCA1 p.Trp590Ser 12509412:130:0
status: NEW132 To elucidate the reason for this functional impairment in the W590S mutant, nucleotide interaction was examined with the wild-type and W590S ABCA1-GFP by using 8-azido-[␣-32 P]ATP.
X
ABCA1 p.Trp590Ser 12509412:132:62
status: NEWX
ABCA1 p.Trp590Ser 12509412:132:135
status: NEW139 B, immunoblots of membranes prepared from HEK293 cells stably expressing the wild-type (4 g, lane 1) or W590S (6 g, lane 2) ABCA1-GFP or from untransfected HEK293 cells (6 g, lane 3).
X
ABCA1 p.Trp590Ser 12509412:139:112
status: NEW141 C, membranes prepared from HEK293 cells stably expressing the wild type (WT) (20 g, lanes 1 and 2) or W590S (30 g, lanes 3 and 4) were incubated with 15 M 8-azido-[␣-32 P]ATP in the absence or presence of 1 mM ortho-vanadate (Vi) and 3 mM MnCl2 for 15 min at 37 °C. Proteins were photoaffinity-labeled with UV irradiation after removal of unbound ligands and analyzed as described under "Experimental Procedures."
X
ABCA1 p.Trp590Ser 12509412:141:110
status: NEW146 W590S ABCA1-GFP showed vanadate-induced nucleotide trapping in the presence of Mn2ϩ .
X
ABCA1 p.Trp590Ser 12509412:146:0
status: NEW148 It has been reported that apoA-I does not properly interact with ATP hydrolysis mutants of ABCA1 (10) and that apoA-I can be interacted with ABCA1-W590S as with the wild-type ABCA1 (17, 35).
X
ABCA1 p.Trp590Ser 12509412:148:27
status: NEWX
ABCA1 p.Trp590Ser 12509412:148:147
status: NEW149 These results suggest that W590S ABCA1-GFP possesses, at least, minimum ATPase activity, which supports apoA-I binding.
X
ABCA1 p.Trp590Ser 12509412:149:0
status: NEWX
ABCA1 p.Trp590Ser 12509412:149:27
status: NEW150 W590S mutation may impair a step after the interaction with apoA-I, such as proper loading of phospholipid and/or cholesterol or proper release of apoA-I after phospholipid/cholesterol loading.
X
ABCA1 p.Trp590Ser 12509412:150:0
status: NEW154 Interestingly, clinical manifestations of these mutations are apparently different (20): R587W is associated with coronary heart disease, whereas W590S is associated with splenomegaly.
X
ABCA1 p.Trp590Ser 12509412:154:146
status: NEW155 In this study, we demonstrated that the defect of HDL assembly in R587W and Q597R is due to the impaired localization of ABCA1 to the PM.
X
ABCA1 p.Trp590Ser 12509412:155:141
status: NEWX
ABCA1 p.Trp590Ser 12509412:155:164
status: NEW156 Subcellular trafficking and vanadate-induced nucleotide trapping in the presence of Mn2ϩ were not impaired in ABCA1-GFP containing the W590S mutation so that W590S seems to have a different type of functional defect.
X
ABCA1 p.Trp590Ser 12509412:156:141
status: NEWX
ABCA1 p.Trp590Ser 12509412:156:164
status: NEW86 The apoA-I-mediated release of cholesterol and choline-phospholipids from HEK293 expressing W590S ABCA1-GFP were 7.4 and 13%, respectively, of those expressing the wild-type ABCA1-GFP, although W590S ABCA1-GFP was localized to the PM as efficiently as the wild type.
X
ABCA1 p.Trp590Ser 12509412:86:92
status: NEWX
ABCA1 p.Trp590Ser 12509412:86:194
status: NEW88 The results were similar to those observed with the stable transformants shown in Fig. 4, A and B. Interaction of ABCA1-GFP with 8-Azido-[ॷ-32 P]ATP-To elucidate the mechanism for the loss of function of ABCA1 in the W590S mutant, we examined the interaction of ABCA1-GFP with ATP.
X
ABCA1 p.Trp590Ser 12509412:88:223
status: NEW101 A, a putative secondary structure of ABCA1 and localization of Tangier Disease mutations R587W, W590S, and Q597R in ECD1.
X
ABCA1 p.Trp590Ser 12509412:101:96
status: NEW106 The wild-type (WT), R587W, W590S, and Q597R ABCA1-GFP were treated with none (afa;), Endo H (H), or PNGaseF (F) and separated with 7% SDS-PAGE.
X
ABCA1 p.Trp590Ser 12509412:106:27
status: NEW110 Cholesterol (A) and choline-phospholipid (B) content in the medium in a 6-well plate containing HEK293 cells stably expressing the wild-type (WT), R587W (RW), W590S (WS), and Q597R (QR) ABCA1-GFP were measured after a 24-h incubation in the presence (black bars) or absence (white bars) of 10 òe;g/ml apoA-I. The relative amount of cholesterol (C) and choline-phospholipid (D) in the medium in a 6-well plate containing HEK293 cells transiently expressing the wild-type (WT), R587W (RW), W590S (WS), and Q597R (QR) ABCA1-GFP was measured after a 24-h incubation in the presence of 10 òe;g/ml apoA-I. The expression levels of mutants were normalized with the GFP fluorescence of cells.
X
ABCA1 p.Trp590Ser 12509412:110:159
status: NEWX
ABCA1 p.Trp590Ser 12509412:110:492
status: NEW112 To determine whether the W590S mutation affects the ATP hydrolysis cycle of ABCA1, vanadate-induced nucleotide trapping in W590S ABCA1-GFP was examined in the presence of Mn2af9; (Fig. 5C).
X
ABCA1 p.Trp590Ser 12509412:112:25
status: NEWX
ABCA1 p.Trp590Ser 12509412:112:123
status: NEW126 This region (R587 to Q597) in ECD1 would be critical for proper folding of ABCA1 and would probably affect the intracellular translocation process, whereas the W590S mutation does not.
X
ABCA1 p.Trp590Ser 12509412:126:160
status: NEW129 W590S ABCA1-GFP was localized to the PM as much as the wild-type ABCA1-GFP when expressed in HEK293.
X
ABCA1 p.Trp590Ser 12509412:129:0
status: NEW131 To elucidate the reason for this functional impairment in the W590S mutant, nucleotide interaction was examined with the wild-type and W590S ABCA1-GFP by using 8-azido-[ॷ-32 P]ATP.
X
ABCA1 p.Trp590Ser 12509412:131:62
status: NEWX
ABCA1 p.Trp590Ser 12509412:131:135
status: NEW138 B, immunoblots of membranes prepared from HEK293 cells stably expressing the wild-type (4 òe;g, lane 1) or W590S (6 òe;g, lane 2) ABCA1-GFP or from untransfected HEK293 cells (6 òe;g, lane 3).
X
ABCA1 p.Trp590Ser 12509412:138:111
status: NEW140 C, membranes prepared from HEK293 cells stably expressing the wild type (WT) (20 òe;g, lanes 1 and 2) or W590S (30 òe;g, lanes 3 and 4) were incubated with 15 òe;M 8-azido-[ॷ-32 P]ATP in the absence or presence of 1 mM ortho-vanadate (Vi) and 3 mM MnCl2 for 15 min at 37 &#b0;C. Proteins were photoaffinity-labeled with UV irradiation after removal of unbound ligands and analyzed as described under "Experimental Procedures."
X
ABCA1 p.Trp590Ser 12509412:140:109
status: NEW145 W590S ABCA1-GFP showed vanadate-induced nucleotide trapping in the presence of Mn2af9; .
X
ABCA1 p.Trp590Ser 12509412:145:0
status: NEW147 It has been reported that apoA-I does not properly interact with ATP hydrolysis mutants of ABCA1 (10) and that apoA-I can be interacted with ABCA1-W590S as with the wild-type ABCA1 (17, 35).
X
ABCA1 p.Trp590Ser 12509412:147:147
status: NEW153 Interestingly, clinical manifestations of these mutations are apparently different (20): R587W is associated with coronary heart disease, whereas W590S is associated with splenomegaly.
X
ABCA1 p.Trp590Ser 12509412:153:146
status: NEW
PMID: 12454269
[PubMed]
Rigot V et al: "Distinct sites on ABCA1 control distinct steps required for cellular release of phospholipids."
No.
Sentence
Comment
140
Three point mutations in the region 580-600 had been reported in Tangier pedigrees (namely R587W, W590S, and Q597R).
X
ABCA1 p.Trp590Ser 12454269:140:98
status: NEW148 This was virtually complete in the case of W590S, Q597R, and ⌬L693, and reduced to one fourth for R587W and C1477R (Table 3).
X
ABCA1 p.Trp590Ser 12454269:148:43
status: NEW170 The last category is illustrated by R587W and W590S Tangier transporters, which are correctly targeted to the plasma membrane, but show a marked functional dissociation.
X
ABCA1 p.Trp590Ser 12454269:170:46
status: NEWX
ABCA1 p.Trp590Ser 12454269:170:301
status: NEW171 Indeed, these variants, while eliciting an apoA-I binding indistinguishable from wild-type ABCA1 (79% Ϯ 5, n ϭ 7, P Ͼ 0.05 and 126% Ϯ 18, n ϭ 6, P Ͼ 0.05 of wild type, respectively) fail to drive both flipping of PS (annexin V binding ϭ 39% Ϯ 11of wild type for R587W, n ϭ 5, P Ͻ 0.05 and 30% Ϯ 9 for W590S, n ϭ 7, P Ͻ 0.01) and membrane release of PL (27% Ϯ 16, n ϭ 3, P Ͻ 0.05 and 16% Ϯ 3, n ϭ 2, P Ͻ 0.01 of wild type, respectively, Table 3), thus indicating that apoA-I binding per se is insufficient for the generation of PL effluxes, which also requires PS flipping.
X
ABCA1 p.Trp590Ser 12454269:171:367
status: NEW205 Morphological and functional evaluation of Tangier- associated ABCA1 variants Identity SL AnnV St ApoA-I St PL Efflux St % % % R587W PM 39 Ϯ 11(5) a 79 Ϯ 5 (7) a 27 Ϯ 16 (3) a W590S PM 30 Ϯ 9 (7) b 126 Ϯ 18 (6) ns 16 Ϯ 3 (2) b Q597R ER, PM 24 Ϯ 9 (4) b 15 Ϯ 8 (4) c 8 Ϯ 7 (2) b ⌬L693 ER 26 Ϯ 11 (5) a 12 Ϯ 6 (4) c nd C1477R PM 53 Ϯ 12 (9) ns 33 Ϯ 9 (6) b 12 Ϯ 2 (2) b HA819/1466 PM 54 Ϯ 12 (6) ns 49 Ϯ 7 (6) a 108 Ϯ 28 (4) b HA819/C1477R PM 57 Ϯ 15 (4) ns 68 Ϯ 6 (4) a 142 Ϯ 24 (2) b SL, subcellular localization as detected by confocal imaging and confirmed by surface biotynilation; AnnV and ApoA-I, binding of annexin V or apoA-I in cells successfully transfected with the test construct (GFP positive); St, statistical significance.
X
ABCA1 p.Trp590Ser 12454269:205:194
status: NEW217 This is the case of the Tangier variant W590S, whose behavior has also been documented by Fitzgerald et al. (22).
X
ABCA1 p.Trp590Ser 12454269:217:40
status: NEW139 We deliberately excluded mutations in the nucleotide binding folds, i.e., those expected to impair function by interference with the ATPase activity, and conversely selected the mutations located in the extracellular region defined by the topological model proposed in Fig. 4A. Three point mutations in the region 580-600 had been reported in Tangier pedigrees (namely R587W, W590S, and Q597R).
X
ABCA1 p.Trp590Ser 12454269:139:376
status: NEW147 This was virtually complete in the case of W590S, Q597R, and L693, and reduced to one fourth for R587W and C1477R (Table 3).
X
ABCA1 p.Trp590Ser 12454269:147:43
status: NEW169 The last category is illustrated by R587W and W590S Tangier transporters, which are correctly targeted to the plasma membrane, but show a marked functional dissociation.
X
ABCA1 p.Trp590Ser 12454269:169:46
status: NEW204 Morphological and functional evaluation of Tangier-associated ABCA1 variants Identity SL AnnV St ApoA-I St PL Efflux St % % % R587W PM 39 11(5) a 79 5 (7) a 27 16 (3) a W590S PM 30 9 (7) b 126 18 (6) ns 16 3 (2) b Q597R ER, PM 24 9 (4) b 15 8 (4) c 8 7 (2) b L693 ER 26 11 (5) a 12 6 (4) c nd C1477R PM 53 12 (9) ns 33 9 (6) b 12 2 (2) b HA819/1466 PM 54 12 (6) ns 49 7 (6) a 108 28 (4) b HA819/C1477R PM 57 15 (4) ns 68 6 (4) a 142 24 (2) b SL, subcellular localization as detected by confocal imaging and confirmed by surface biotynilation; AnnV and ApoA-I, binding of annexin V or apoA-I in cells successfully transfected with the test construct (GFP positive); St, statistical significance.
X
ABCA1 p.Trp590Ser 12454269:204:175
status: NEW216 This is the case of the Tangier variant W590S, whose behavior has also been documented by Fitzgerald et al. (22).
X
ABCA1 p.Trp590Ser 12454269:216:40
status: NEW
PMID: 12407001
[PubMed]
Hong SH et al: "Lack of association between increased carotid intima-media thickening and decreased HDL-cholesterol in a family with a novel ABCA1 variant, G2265T."
No.
Sentence
Comment
89
Other mutations in ABCA1 associated with TD and in close proximity to W590S have been identified in amino acids 587 and 597 (3, 27).
X
ABCA1 p.Trp590Ser 12407001:89:70
status: NEW90 Finally, Bodzioch et al. (4) reported a mutation in an individual with TD at the same nucleotide (2265) that led to a predicted conversion of Trp to Ser (W590S).
X
ABCA1 p.Trp590Ser 12407001:90:154
status: NEW
PMID: 12084722
[PubMed]
Fitzgerald ML et al: "Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I."
No.
Sentence
Comment
4
Four of five mutants had a marked decline in cross-linking to apoA-I, whereas one (W590S) retained full cross-linking activity.
X
ABCA1 p.Trp590Ser 12084722:4:83
status: NEW7 The behavior of the W590S mutant indicates that although binding of apoA-I by ABCA1 may be necessary, it is not sufficient for stimulation of cholesterol efflux.
X
ABCA1 p.Trp590Ser 12084722:7:20
status: NEW39 DNA Constructs-Five missense mutants of ABCA1 (R587W, W590S, Q597R, C1477R, and S1506L) were generated using overlap polymerase chain reaction methods, as described previously (17).
X
ABCA1 p.Trp590Ser 12084722:39:54
status: NEW70 Missense Mutations in Two Putative Extracellular Loops of ABCA1 Ablate Efflux Activity-Five missense mutations (R587W, W590S, Q597R, C1477R, and S1506L) were introduced into a wild type ABCA1 cDNA using PCR mutagenesis techniques.
X
ABCA1 p.Trp590Ser 12084722:70:119
status: NEW71 Three of these mutations (R587W, W590S, and Q597R) fall in a tight cluster within the large N-terminal loop at a point near the putative second transmembrane domain shown in Fig. 3.
X
ABCA1 p.Trp590Ser 12084722:71:33
status: NEW116 The cells were transfected with either empty vector (mock), wild type ABCA1 (WT), or ABCA1 constructs carrying the indicated point mutations (R587W, W590S, Q597R, C1477R, and S1506L).
X
ABCA1 p.Trp590Ser 12084722:116:149
status: NEW119 Absolute apoA-I and medium efflux values, respectively, are as follows: mock, 1.59 Ϯ 0.04% versus 1.21 Ϯ 0.39%; WT, 3.92 Ϯ 0.13% versus 1.9 Ϯ 0.08%; R587W, 1.78 Ϯ 0.11% versus 1.61 Ϯ 0.24%; W590S, 1.92 Ϯ 0.24% versus 1.63 Ϯ 0.08%; Q597R, 1.5 Ϯ 0.14% versus 1.49 Ϯ 0.03%; C1477R, 1.67 Ϯ 0.18% versus 1.52 Ϯ 0.15%; and S1506L, 1.66 Ϯ 0.28% versus 1.6 Ϯ 0.13%.
X
ABCA1 p.Trp590Ser 12084722:119:226
status: NEW200 Surprisingly, the W590S mutant consistently cross-linked to apoA-I at an efficiency that was equal to or greater than that of wild type ABCA1.
X
ABCA1 p.Trp590Ser 12084722:200:18
status: NEW202 DISCUSSION In this study, we have established that several naturally occurring missense mutations in ABCA1 (R587W, W590S, Q597R, C1477R, and S1506L) located in the two largest loop domains of the protein (comprising amino acids ϳ44-640 and ϳ1371-1649, respectively) are, in fact, loss-of-function mutations.
X
ABCA1 p.Trp590Ser 12084722:202:115
status: NEW212 Although three of the mutations (Q597R, C1477R, and S1506L) showed no appreciable cross-linking to apoA-I, the R587W mutant had an intermediate activity, and the W590S mutant retained full, if not enhanced, cross-linking to the apoprotein.
X
ABCA1 p.Trp590Ser 12084722:212:162
status: NEW263 What is clear is that a direct interaction between apoA-I and ABCA1 is not sufficient for the movement of cholesterol out of the cell, because the W590S mutant retained full cross-linking activity and yet could not efflux cholesterol.
X
ABCA1 p.Trp590Ser 12084722:263:147
status: NEW37 DNA Constructs-Five missense mutants of ABCA1 (R587W, W590S, Q597R, C1477R, and S1506L) were generated using overlap polymerase chain reaction methods, as described previously (17).
X
ABCA1 p.Trp590Ser 12084722:37:54
status: NEW67 Missense Mutations in Two Putative Extracellular Loops of ABCA1 Ablate Efflux Activity-Five missense mutations (R587W, W590S, Q597R, C1477R, and S1506L) were introduced into a wild type ABCA1 cDNA using PCR mutagenesis techniques.
X
ABCA1 p.Trp590Ser 12084722:67:119
status: NEW68 Three of these mutations (R587W, W590S, and Q597R) fall in a tight cluster within the large N-terminal loop at a point near the putative second transmembrane domain shown in Fig. 3.
X
ABCA1 p.Trp590Ser 12084722:68:33
status: NEW112 The cells were transfected with either empty vector (mock), wild type ABCA1 (WT), or ABCA1 constructs carrying the indicated point mutations (R587W, W590S, Q597R, C1477R, and S1506L).
X
ABCA1 p.Trp590Ser 12084722:112:149
status: NEW115 Absolute apoA-I and medium efflux values, respectively, are as follows: mock, 1.59 afe; 0.04% versus 1.21 afe; 0.39%; WT, 3.92 afe; 0.13% versus 1.9 afe; 0.08%; R587W, 1.78 afe; 0.11% versus 1.61 afe; 0.24%; W590S, 1.92 afe; 0.24% versus 1.63 afe; 0.08%; Q597R, 1.5 afe; 0.14% versus 1.49 afe; 0.03%; C1477R, 1.67 afe; 0.18% versus 1.52 afe; 0.15%; and S1506L, 1.66 afe; 0.28% versus 1.6 afe; 0.13%.
X
ABCA1 p.Trp590Ser 12084722:115:226
status: NEW192 Surprisingly, the W590S mutant consistently cross-linked to apoA-I at an efficiency that was equal to or greater than that of wild type ABCA1.
X
ABCA1 p.Trp590Ser 12084722:192:18
status: NEW194 DISCUSSION In this study, we have established that several naturally occurring missense mutations in ABCA1 (R587W, W590S, Q597R, C1477R, and S1506L) located in the two largest loop domains of the protein (comprising amino acids b03;44-640 and b03;1371-1649, respectively) are, in fact, loss-of-function mutations.
X
ABCA1 p.Trp590Ser 12084722:194:115
status: NEW204 Although three of the mutations (Q597R, C1477R, and S1506L) showed no appreciable cross-linking to apoA-I, the R587W mutant had an intermediate activity, and the W590S mutant retained full, if not enhanced, cross-linking to the apoprotein.
X
ABCA1 p.Trp590Ser 12084722:204:162
status: NEW254 What is clear is that a direct interaction between apoA-I and ABCA1 is not sufficient for the movement of cholesterol out of the cell, because the W590S mutant retained full cross-linking activity and yet could not efflux cholesterol.
X
ABCA1 p.Trp590Ser 12084722:254:147
status: NEW
PMID: 23221702
[PubMed]
Tomioka M et al: "The effects of neurological disorder-related codon variations of ABCA13 on the function of the ABC protein."
No.
Sentence
Comment
56
ApoA-I-dependent free cholesterol efflux from HEK293 cells stably expressing ABCA1, non-functional mutant (MM), a Tangier mutant (W590S), and SNP mutants are shown.
X
ABCA1 p.Trp590Ser 23221702:56:130
status: NEW68 We also analyzed cholesterol efflux from cells expressing non-functional ABCA1-MM, in which two critical lysine residues in the NBDs were replaced with methionine residues and a Tangier disease mutant, ABCA1-W590S.
X
ABCA1 p.Trp590Ser 23221702:68:208
status: NEW69 When the cells were incubated with a physiological concentration of apoA-I (10 mg/mL) for 24 h, a significant amount of cholesterol was transported from them to the medium by ABCA1 (Fig. 2A), but we found that ABCA1-MM did not mediate apoA-I-dependent cholesterol efflux, and that W590S Tangier mutation reduced cholesterol efflux by about 55%, as reported previously.12) Furthermore, the T1088A SNP drastically reduced cholesterol efflux, by about 90%.
X
ABCA1 p.Trp590Ser 23221702:69:208
status: NEWX
ABCA1 p.Trp590Ser 23221702:69:281
status: NEW70 However, the K2031C SNP did not significantly affect cholesterol efflux as compared to the wild type or K2031R (Fig. 2A).
X
ABCA1 p.Trp590Ser 23221702:70:281
status: NEW76 The total expression of T1088A was similar to that of the wild-type and the other mutants, with the exception of W590S (Fig. 3A).
X
ABCA1 p.Trp590Ser 23221702:76:113
status: NEW77 However, the amount of biotinylated ABCA1-T1088A was low as compared with the other mutants, and the fraction of surface localization was reduced by about 70% as compared to ABCA1-MM (Fig. 3B).
X
ABCA1 p.Trp590Ser 23221702:77:113
status: NEW87 A B W590S Fig. 3.
X
ABCA1 p.Trp590Ser 23221702:87:4
status: NEW57 ApoA-I-dependent free cholesterol efflux from HEK293 cells stably expressing ABCA1, non-functional mutant (MM), a Tangier mutant (W590S), and SNP mutants are shown.
X
ABCA1 p.Trp590Ser 23221702:57:130
status: NEW88 A B W590S Fig. 3.
X
ABCA1 p.Trp590Ser 23221702:88:4
status: NEW
PMID: 23479619
[PubMed]
Nagata KO et al: "ABCA1 dimer-monomer interconversion during HDL generation revealed by single-molecule imaging."
No.
Sentence
Comment
236
16. Nagao K, Zhao Y, Takahashi K, Kimura Y, Ueda K (2009) Sodium taurocholate-dependent lipid efflux by ABCA1: Effects of W590S mutation on lipid translocation and apolipoprotein A-I dissociation.
X
ABCA1 p.Trp590Ser 23479619:236:122
status: NEW
PMID: 23543682
[PubMed]
Lyssenko NN et al: "Factors controlling nascent high-density lipoprotein particle heterogeneity: ATP-binding cassette transporter A1 activity and cell lipid and apolipoprotein AI availability."
No.
Sentence
Comment
37
MATERIALS AND METHODS Cell culture and biogenesis of nascent HDL BHK-ABCA1, BHK-ABCA1(W590S), and BHK-ABCA1(C1477R) cells expressing human wild-type or mutant ABCA1 have been previously described (36, 37).
X
ABCA1 p.Trp590Ser 23543682:37:86
status: NEW166 Mutations in ABCA1 that compromise its functionality shift nascent HDL production to the smaller particle species W590S and C1477R are naturally occurring mutations in human ABCA1 that impair its functionality and cause Tangier disease (49) but do not affect its subcellular localization or expression levels (37).
X
ABCA1 p.Trp590Ser 23543682:166:114
status: NEW167 To determine how deficiency in ABCA1 functionality affects size heterogeneity of nascent HDL particles, BHK-ABCA1, BHK-ABCA1(W590S), and BHK-ABCA1(C1477R) cells were plated at the same density, labeled with [3 H]cholesterol, induced to express ABCA1 at the maximum level, and exposed to a high concentration of human lipid-free apoAI, followed by the regular procedure to collect and analyze nascent HDL via gel filtration.
X
ABCA1 p.Trp590Ser 23543682:167:125
status: NEW194 BHK cells expressing wild-type ABCA1, ABCA1(W590S), or ABCA1(C1477R) were plated at the same density, labeled with [3 H]cholesterol, treated with 10 nM mifepristone, and exposed to 10 òe;g/ml of human apoAI to generate nascent HDL.
X
ABCA1 p.Trp590Ser 23543682:194:44
status: NEW195 The decreased size of gel-filtration elution peaks indicates that W590S and especially C1477R mutations dramatically reduced the ability of ABCA1 to facilitate nascent HDL assembly.
X
ABCA1 p.Trp590Ser 23543682:195:66
status: NEW
PMID: 23559627
[PubMed]
Wang S et al: "ABCA1 mediates unfolding of apolipoprotein AI N terminus on the cell surface before lipidation and release of nascent high-density lipoprotein."
No.
Sentence
Comment
1
One recent model from Phillips proposes that ABCA1 shuttles phospholipids from the inner to extracellular face of the plasma membrane, resulting in membrane bulges with high curvature that are sufficient to allow apoAI penetration and nHDL formation.4 Mutations in ABCA1 lead to Tangier disease and familial hypoalphalipoproteinemia, characterized by very low levels of plasma HDL-cholesterol.5 Functional studies of certain Tangier disease mutations that are properly trafficked to the plasma membrane demonstrate that ABCA1 seems to have at least 2 distinct activities6 : apoAI binding and plasma membrane remodeling, the latter demonstrated through phosphatidylserine (PS) translocation to the outer leaflet of the plasma membrane.7 The W590S mutation in the first extracellular domain of ABCA1 is defective in PS translocation, but competent for apoAI binding.5,7,8 In contrast, the C1477R mutation in the second extracellular domain of ABCA1 is defective in apoAI binding, but competent for PS translocation.7 Further demonstration of the ability of ABCA1, and the deficit of W590S isoform, to remodel the plasma membrane was provided by Nagao et al,8 who used sodium taurocholate (NaTC) as a weak detergent extracellular lipid acceptor; wild type (WT) but not W590S ABAC1 mediates increased lipid efflux to NaTC.
X
ABCA1 p.Trp590Ser 23559627:1:740
status: NEWX
ABCA1 p.Trp590Ser 23559627:1:1081
status: NEWX
ABCA1 p.Trp590Ser 23559627:1:1266
status: NEW4 Approach and Results-HEK293 cells were stably transfected with ABCA1 vectors, encoding wild type, and the W590S and C1477R Tangier disease mutation isoforms, along with the K939M ATP-binding domain mutant.
X
ABCA1 p.Trp590Ser 23559627:4:106
status: NEW6 The W590S isoform had decreased plasma membrane remodeling and lipid efflux activities, and the C1477R isoform had decreased apoAI binding, and lipid efflux activities, whereas the K939M isoform did not bind apoAI, remodel the membrane, or efflux cholesterol.
X
ABCA1 p.Trp590Ser 23559627:6:4
status: NEW24 HEK293 cells were stably transfected with different murine ABCA1-green fluorescent protein (GFP) fusion vectors encoding WT, K939M, W590S, and C1477R isoforms, the latter 2 identified as Tangier disease-causing mutations in the first and second large extracellular domains, respectively.6 Several clonally derived cell lines from each construction were screened by confocal fluorescence microscopy and flow cytometry to select lines for further study with equivalent ABCA1 expression.
X
ABCA1 p.Trp590Ser 23559627:24:132
status: NEW25 As previously described,5,9 WT, W590S, C1477R, and K939M ABCA1-GFP fusions were processed correctly in cells and expressed on the plasma membrane (Figure 1A).
X
ABCA1 p.Trp590Ser 23559627:25:32
status: NEW28 We confirmed the previously identified apoAI-binding activity of the WT and W590S-ABCA1 isoforms, with both having ࣈ6-fold higher apoAI binding than the control cells (P<0.001 by ANOVA posttest).
X
ABCA1 p.Trp590Ser 23559627:28:76
status: NEW33 The W590S cells had a small 1.26-fold increase in cell surface PS (P<0.05 versus control by ANOVA posttest), whereas the K939M-ABCA1 isoform had no cell surface PS increase (Figure 2B).
X
ABCA1 p.Trp590Ser 23559627:33:4
status: NEW34 Thus, our results confirmed previous findings by Singaraja et al5 and Nagao et al8 that the W590S mutation in ABCA1`s first extracellular domain greatly diminishes PS floppase activity indicative of a defect in plasma membrane remodeling, whereas the C1477R mutation in its second large extracellular domain abolishes apoAI binding.
X
ABCA1 p.Trp590Ser 23559627:34:92
status: NEW36 In the absence of any acceptor, WT ABCA1 increased basal 3 H cholesterol efflux by 32% (P<0.05 by ANOVA posttest versus HEK), which has previously been shown to be attributable to increased microparticle release.14 The C1477R-ABCA1 isoform also had increased basal cholesterol efflux activity (34% increase; P<0.05); however, efflux from the W590S-ABCA1 isoform cell line was not significantly different from the control HEK cells.
X
ABCA1 p.Trp590Ser 23559627:36:342
status: NEW39 A, Confocal microscopy of wild type (WT), W590S, C1477R, and K939M ABCA1-GFP isoforms shows cell surface expression.
X
ABCA1 p.Trp590Ser 23559627:39:42
status: NEW40 B, Similar expression levels of WT, W590S, C1477R, and K939M ABCA1-GFP cell lines shown by flow cytometry (n=3; mean&#b1;SD; different numbers above the bars show P<0.001, by ANOVA posttest).
X
ABCA1 p.Trp590Ser 23559627:40:36
status: NEW42 Interestingly, both Tangier disease mutations supported partial efflux to apoAI with 4.27and 4.02-fold increases above the control HEK cells for the W590S and C1477R isoforms, respectively.
X
ABCA1 p.Trp590Ser 23559627:42:149
status: NEW43 All 4 cell lines have significantly different efflux to apoAI (P<0.001 by ANOVA posttest), except for efflux from the W590S and C1477R cells that were not different from each other.
X
ABCA1 p.Trp590Ser 23559627:43:118
status: NEW46 The W590S-ABCA1 isoform, which can mediate binding of apoAI, yielded a similar cholesterol efflux as the HEK cells at 2.57%.
X
ABCA1 p.Trp590Ser 23559627:46:4
status: NEW49 Thus, our findings show that ABCA1 mutations that disrupt either plasma membrane remodeling (W590S) or apoAI binding (C1477R) are still competent to mediate cholesterol efflux to apoAI, albeit at reduced efficiency.
X
ABCA1 p.Trp590Ser 23559627:49:93
status: NEW62 A, Alexa647-labeled apoAI binding to nontransfected cells (HEK) and cells stably transfected with wild type (WT), W590S, C1477R, and K939M ABCA1-green fluorescent protein (GFP) vectors assayed by flow cytometry (n=3; mean&#b1;SD; P<0.0005 for HEK in the presence or absence of labeled apoAI by t test; for the 5 cell types in the presence of labeled apoAI different numbers above the bars show P<0.001; by ANOVA posttest).
X
ABCA1 p.Trp590Ser 23559627:62:114
status: NEW64 C, Cholesterol efflux from control HEK cells and WT, W590S, and C1477R ABCA1-GFP transfected cells in the absence of exogenous acceptors or in the presence of 5 bc;g/mL apoAI or 2 mmol/L sodium taurocholate (NaTC; n=3; mean&#b1;SD; different numbers above the bars show P<0.05, by ANOVA posttest).
X
ABCA1 p.Trp590Ser 23559627:64:53
status: NEW71 However, on incubation of this indicator with the WT and W590S ABCA1-expressing cells, there was a rightward shift to a higher cellular Bodipy-TMR/Alexa647 ratio peak of 1.3 to 1.4 (1.86-2.0-fold increase).
X
ABCA1 p.Trp590Ser 23559627:71:57
status: NEW74 The partially active W590S isoform has 2 activities: apoAI binding and apoAI unfolding.
X
ABCA1 p.Trp590Ser 23559627:74:21
status: NEW92 The W590S and C1447R mutant isoforms had intermediate ratios ࣈ1.4 and 1.2-fold higher than that observed from the control HEK cells (P<0.001 and P<0.05, respectively, versus control cells by ANOVA posttest).
X
ABCA1 p.Trp590Ser 23559627:92:4
status: NEW94 We attribute the intermediate fluorescence ratio levels in the conditioned media from the W590S and C1447R transfected cells to be a result of fewer lipidated particles released into the conditioned media, rather than to less unfolding of apoAI per particle.
X
ABCA1 p.Trp590Ser 23559627:94:90
status: NEW113 We chose to further study 2 specific mutations in the first (W590S) and second (C1477R) extracellular domains, respectively, based on their previously identified distinct activities.
X
ABCA1 p.Trp590Ser 23559627:113:61
status: NEW114 Fitzgerald et al17 examined 5 Tangier disease mutations that mapped to the 2 large extracellular domains, and reported that only the W590S mutation in the first extracellular domain was still competent to mediate apoAI cross-linking, whereas other mutations in the first (R587W and Q597R) and second (C1477R and S1506L) extracellular domains could not mediate apoAI cross-linking.
X
ABCA1 p.Trp590Ser 23559627:114:133
status: NEW115 Although the flag-tagged R587W and Q597R variants were reported to be expressed on the plasma membrane in transfected cells,17 2 other independent groups reported that these 2 variants have impaired processing and decreased cell surface expression5,8,18 ; but all agree that the W590S is expressed on the plasma membrane similarly to the WT isoform and can mediate apoAI binding.
X
ABCA1 p.Trp590Ser 23559627:115:279
status: NEW116 Our findings reproduce that the W590S isoform has plasma membrane localization and WT levels of apoAI-binding activity; and that it has partial cholesterol efflux activity to extracellular apoAI compared with the WT isoform, as previously demonstrated.5,7,8,18 We chose to study the C1477R mutation in the second extracellular domain because it is processed correctly to the plasma membrane and has defective apoAI binding,5,7,17 but it retains its PS translocase activity and partial efflux activity,7 all findings that we confirmed in the current study, where we found ࣈ50% cholesterol efflux activity to apoAI.
X
ABCA1 p.Trp590Ser 23559627:116:32
status: NEW117 Nagao et al8 first demonstrated the use of NaTC as a nonpeptide acceptor of cellular lipids, and that WT ABCA1 increased lipid efflux to this weak detergent, and that the W590S mutation abolished this activity.
X
ABCA1 p.Trp590Ser 23559627:117:171
status: NEW118 Here, we compared the acceptor activity of NaTC for cells expressing WT, W590S, and C1477R-ABCA1 isoforms, and found that the C1477R mutant has equivalent efflux to NaTC as the WT isoform, whereas the W590S mutant has no detectable efflux to NaTC above nontransfected cells.
X
ABCA1 p.Trp590Ser 23559627:118:73
status: NEWX
ABCA1 p.Trp590Ser 23559627:118:201
status: NEW119 The NaTC efflux activities of these ABCA1 isoforms is similar to the PS translocase activity, and thus both of these assays are evidence that the WT and C1477R isoforms can remodel the plasma membrane, whereas the W590S isoform is mostly deficient in this activity.
X
ABCA1 p.Trp590Ser 23559627:119:214
status: NEW130 Through the use of an N-terminal apoAI unfolding indicator, we observed what we estimate to be ࣈ75% unfolding of apoAI on the surface of HEK cells expressing either WT or W590S-ABCA1 isoforms, both of which have full apoAI-binding activity (Figure 4A).
X
ABCA1 p.Trp590Ser 23559627:130:177
status: NEW131 The slight rightward shift of the W590S isoform may be as a result of defective membrane remodeling in the W590S-expressing cells, leading to the unfolded apoAI having fewer opportunities to form rHDL and be released from the cell.
X
ABCA1 p.Trp590Ser 23559627:131:34
status: NEWX
ABCA1 p.Trp590Ser 23559627:131:107
status: NEW138 The presence of the high-affinity apoAI-binding site in WT and W590S-ABCA1 isoforms would promote apoAI proximity to the low-affinity binding site and therefore increase apoAI unfolding.
X
ABCA1 p.Trp590Ser 23559627:138:63
status: NEW149 A model for the mechanism of ABCA1 action from Phillips states that phospholipid translocation produces membrane protuberances that in themselves because of their small radius and surface packing are sufficient to spontaneously interact with apoAI and form nHDL.4 However, the observation that the W590S-ABCA1 isoform is not competent for phospholipid translocation and membrane remodeling but is still able to mediate HDL assembly, albeit at reduced efficiency, does not support this model.
X
ABCA1 p.Trp590Ser 23559627:149:298
status: NEW161 We propose the steps through formation of the LC state may be reversible, and there is experimental evidence that W590S ABCA1-expressing cells bind and release nonlipidated apoAI from the cell,30 and we show here that the apoAI bound by this mutant isoform is also in the U state.
X
ABCA1 p.Trp590Ser 23559627:161:114
status: NEW
PMID: 24097981
[PubMed]
Quazi F et al: "Differential phospholipid substrates and directional transport by ATP-binding cassette proteins ABCA1, ABCA7, and ABCA4 and disease-causing mutants."
No.
Sentence
Comment
65
Mutations introduced by overlap extension PCR using Pfu AD DNA polymerase in ABCA1 included S100C, W590S, F593L, N935S, T929I, C1477R, T1512M, R2081W, and P2150L.
X
ABCA1 p.Trp590Ser 24097981:65:99
status: NEW67 ABCA1-MM was constructed to harbor the Walker A-motif lysine-to-methionine mutations K939M/K1952M by the nested PCR method; ABCA4-MM had the corresponding K969M/ K1969M Walker A mutations (37), and ABCA7-MM had the Lipid Transport Activity of ABCA Transporters NOVEMBER 29, 2013ߦVOLUME 288ߦNUMBER 48 JOURNAL OF BIOLOGICAL CHEMISTRY 34415 at SEMMELWEIS UNIV OF MEDICINE on December 3, K847M/K1833M Walker A mutations.
X
ABCA1 p.Trp590Ser 24097981:67:99
status: NEW208 Expression and Purification of Disease-causing ABCA1 and ABCA4 Mutants-As part of this study, we have generated a number of disease-causing mutations in ABCA1 and ABCA4 to determine their effect on the expression and functional properties of these transporters. We focused our studies on nine missense mutations in ABCA1 known to cause Tangier disease, including three (S100C, W590S, and F593L) in ECD1, two (T929I and N935S) in the NBD1, two (C1477R and T1512M) in ECD2, one (R2081W) in NBD2, and one (P2150L) in the C-terminal segment as shown in Fig. 6A (blue).
X
ABCA1 p.Trp590Ser 24097981:208:377
status: NEW229 Variants in the ECD1 (S100C, W590S, and F593L), NBD1 (T929I and N935S), and NBD2 (R2081W) of ABCA1 showed significantly reduced ATPase activities in the range of 20-35% of WT activity (Fig. 7A).
X
ABCA1 p.Trp590Ser 24097981:229:29
status: NEW232 ABCA4 variants showed a similar ATPase activity profile as the ABCA1 mutants with the exception of the T1537M mutation of ABCA4, which was significantly lower than the corresponding T1512M mutant in ABCA1.
X
ABCA1 p.Trp590Ser 24097981:232:29
status: NEW251 Some disease alleles such as W590S, C1477R, and P2150L (ABCA1) have conserved residues in ABCA4, but mutations in these positions in ABCA4 have yet to be linked to Stargardt disease.
X
ABCA1 p.Trp590Ser 24097981:251:29
status: NEW295 The ABCA1/ABCA4 mutants in the ECD1 (S100C/S100P, W590S/ W605S, and F593L/F608L) displayed the lowest activities (20-30% WT), whereas those in the ECD2 (C1477R/C1502R and T1512M/T1537M) and the P2150L/P2180L mutants in the C terminus showed the highest activities (60-100% WT).
X
ABCA1 p.Trp590Ser 24097981:295:50
status: NEW211 Expression and Purification of Disease-causing ABCA1 and ABCA4 Mutants-As part of this study, we have generated a number of disease-causing mutations in ABCA1 and ABCA4 to determine their effect on the expression and functional properties of these transporters. We focused our studies on nine missense mutations in ABCA1 known to cause Tangier disease, including three (S100C, W590S, and F593L) in ECD1, two (T929I and N935S) in the NBD1, two (C1477R and T1512M) in ECD2, one (R2081W) in NBD2, and one (P2150L) in the C-terminal segment as shown in Fig. 6A (blue).
X
ABCA1 p.Trp590Ser 24097981:211:377
status: NEW254 Some disease alleles such as W590S, C1477R, and P2150L (ABCA1) have conserved residues in ABCA4, but mutations in these positions in ABCA4 have yet to be linked to Stargardt disease.
X
ABCA1 p.Trp590Ser 24097981:254:29
status: NEW298 The ABCA1/ABCA4 mutants in the ECD1 (S100C/S100P, W590S/ W605S, and F593L/F608L) displayed the lowest activities (20-30% WT), whereas those in the ECD2 (C1477R/C1502R and T1512M/T1537M) and the P2150L/P2180L mutants in the C terminus showed the highest activities (60-100% WT).
X
ABCA1 p.Trp590Ser 24097981:298:50
status: NEW64 Mutations introduced by overlap extension PCR using Pfu AD DNA polymerase in ABCA1 included S100C, W590S, F593L, N935S, T929I, C1477R, T1512M, R2081W, and P2150L.
X
ABCA1 p.Trp590Ser 24097981:64:99
status: NEW206 Expression and Purification of Disease-causing ABCA1 and ABCA4 Mutants-As part of this study, we have generated a number of disease-causing mutations in ABCA1 and ABCA4 to determine their effect on the expression and functional properties of these transporters. We focused our studies on nine missense mutations in ABCA1 known to cause Tangier disease, including three (S100C, W590S, and F593L) in ECD1, two (T929I and N935S) in the NBD1, two (C1477R and T1512M) in ECD2, one (R2081W) in NBD2, and one (P2150L) in the C-terminal segment as shown in Fig. 6A (blue).
X
ABCA1 p.Trp590Ser 24097981:206:377
status: NEW227 Variants in the ECD1 (S100C, W590S, and F593L), NBD1 (T929I and N935S), and NBD2 (R2081W) of ABCA1 showed significantly reduced ATPase activities in the range of 20-35% of WT activity (Fig. 7A).
X
ABCA1 p.Trp590Ser 24097981:227:29
status: NEW249 Some disease alleles such as W590S, C1477R, and P2150L (ABCA1) have conserved residues in ABCA4, but mutations in these positions in ABCA4 have yet to be linked to Stargardt disease.
X
ABCA1 p.Trp590Ser 24097981:249:29
status: NEW293 The ABCA1/ABCA4 mutants in the ECD1 (S100C/S100P, W590S/ W605S, and F593L/F608L) displayed the lowest activities (2030% WT), whereas those in the ECD2 (C1477R/C1502R and T1512M/T1537M) and the P2150L/P2180L mutants in the C terminus showed the highest activities (60-100% WT).
X
ABCA1 p.Trp590Ser 24097981:293:50
status: NEW
PMID: 24220029
[PubMed]
Gulshan K et al: "Sphingomyelin depletion impairs anionic phospholipid inward translocation and induces cholesterol efflux."
No.
Sentence
Comment
5
The Tangier disease W590S ABCA1 mutation has defective PS floppase activity and diminished cholesterol efflux activity.
X
ABCA1 p.Trp590Ser 24220029:5:20
status: NEW8 Depletion of sphingomyelin in stably transfected HEK293 cells expressing the Tangier disease W590S mutant ABCA1 isoform rescued the defect in PS exposure and restored cholesterol efflux to apoAI.
X
ABCA1 p.Trp590Ser 24220029:8:93
status: NEW22 The W590S Tangier mutant allele of ABCA1 retains its ability to bind lipid-free lipoprotein apoAI, but has impaired PS floppase activity and efflux of phospholipids and cholesterol to apoAI (15, 24-26).
X
ABCA1 p.Trp590Ser 24220029:22:4
status: NEW38 We found that SM depletion by myriocin or sphingomyelinase (SMase) treatment could compensate for the defective PS floppase activity of the mutant W590S-ABCA1 isoform, restoring its cholesterol efflux activity to apoAI.
X
ABCA1 p.Trp590Ser 24220029:38:147
status: NEW105 RESULTS Myriocin Enhances Cholesterol Efflux and Restores Efflux Activity of the W590S Abca1 Mutation-We assessed the effects of myriocin, a potent inhibitor of the first step in sphingolipid synthesis on cholesterol efflux to apoAI, a process that is mediated by ABCA1, in stably transfected HEK293 cells expressing equivalent levels of wild type (WT) murine and two mutant ABCA1 isoforms (15).
X
ABCA1 p.Trp590Ser 24220029:105:81
status: NEW107 As previously observed (15, 24-26), cholesterol efflux to apoAI from cells expressing either the W590S (PS translocation deficient) or C1477R (apoAI binding deficient) ABCA1 mutant isoforms was partially, but not completely impaired compared with the WT isoform (p b0d; 0.001 compared with control HEK and WT ABCA1 by ANOVA post test).
X
ABCA1 p.Trp590Ser 24220029:107:97
status: NEW108 Upon treatment with 10 òe;M myriocin, cholesterol efflux was significantly increased in all four cell types, however, the net increase was greatest for the W590S mutant isoform (2.34% increase, 1.72-fold), with the wild type ABCA1 isoform having a 1.44% net increase, and the other two cell lines having b0d;1% net increases.
X
ABCA1 p.Trp590Ser 24220029:108:160
status: NEW109 Thus, myriocin treatment could overcome much of the impaired cholesterol efflux activity of the W590S Abca1 mutation, although not greatly improving efflux from the C1477R mutation.
X
ABCA1 p.Trp590Ser 24220029:109:96
status: NEW123 We then compared the effects of depleting sphingomyelin on the cholesterol efflux activity of the WT and W590S isoforms of ABCA1 in stably transfected HEK cells.
X
ABCA1 p.Trp590Ser 24220029:123:105
status: NEW124 Increasing levels of SMase led to increased cholesterol efflux to apoAI for both isoforms, such that at the highest dose of SMase, the W590S isoform had as much efflux activity as the WT isoform in the absence of SMase (Fig. 3G).
X
ABCA1 p.Trp590Ser 24220029:124:135
status: NEW125 Thus, we could obtain complete restoration of the efflux activity of the ABCA1 W590S isoform FIGURE 1.
X
ABCA1 p.Trp590Ser 24220029:125:79
status: NEW127 A, myriocin compensates for the W590S-Abca1 mutation.
X
ABCA1 p.Trp590Ser 24220029:127:32
status: NEW128 Non-transfected HEK293 cells along with HEK cells transfected with WT-Abca1-GFP, W590S-Abca1-GFP, or C1477R-Abca1-GFP isoforms were incubated with radiolabeled cholesterol and subsequently chased with apoAI (5 òe;g/ml) for 6 h.
X
ABCA1 p.Trp590Ser 24220029:128:81
status: NEW142 Taken together, our data strongly indicate that Sphingomyelin Depletion Impairs Phospholipid Flip 37170 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288ߦNUMBER 52ߦDECEMBER 27, 2013 decreased SM, rather than increased ceramide, is responsible for the induction of cholesterol efflux, which can compensate for the impaired PS translocation in the W590S ABCA1 mutation.
X
ABCA1 p.Trp590Ser 24220029:142:352
status: NEW147 Although WT ABCA1 expression increased cholesterol efflux to NaTC to almost 6-fold, expression of the W590S ABCA1 isoform increased efflux to NaTC by only 3.1-fold, as previously observed (15, 25).
X
ABCA1 p.Trp590Ser 24220029:147:102
status: NEW148 Myriocin increased cholesterol efflux from cells expressing either ABCA1 isoforms (1.6-fold for the WT and 2.1-fold for the W590S isoform), such that the myriocin-treated W590S-expressing cells exhibited comparable efflux to NaTC as seen in the myriocin-untreated WT-ABCA1 expressing cells (see gray bars in Fig. 4B).
X
ABCA1 p.Trp590Ser 24220029:148:124
status: NEWX
ABCA1 p.Trp590Ser 24220029:148:171
status: NEW149 Thus, the SM depletion effect on cholesterol efflux is observed both in the absence and presence of ABCA1 expression, and can compensate for the W590S Abca1 mutation even with a non-selective acceptor.
X
ABCA1 p.Trp590Ser 24220029:149:145
status: NEW151 Because the ABCA1 W590S mutation has defective translocation of PS to the outer leaflet of the plasma membrane (11, 24), we assessed whether SM depletion altered the translocation of phospholipids across the plasma membrane.
X
ABCA1 p.Trp590Ser 24220029:151:18
status: NEW154 As reported earlier, the W590S-Abca1 expressing HEK cells showed decreased cell surface PS as compared with the WT isoform (15, 24, 25), only 1.3-fold higher than control HEK cells.
X
ABCA1 p.Trp590Ser 24220029:154:25
status: NEW173 HEK cells stably transfected with either WT-Abca1-GFP or W590S-Abca1-GFP isoforms were loaded with radiolabeled cholesterol and chased with apoAI (5 òe;g/ml) for 6 h.
X
ABCA1 p.Trp590Ser 24220029:173:57
status: NEW180 HEK293 cells or stably transfected lines with either WT or W590S isoform of Abca1 were incubated with radiolabeled cholesterol and subsequently treated with or without 10 òe;M myriocin for 12 h.
X
ABCA1 p.Trp590Ser 24220029:180:59
status: NEW184 Here, different letters above the bars show p b0d; 0.01 by ANOVA with a Bonferroni post test. Sphingomyelin Depletion Impairs Phospholipid Flip DECEMBER 27, 2013ߦVOLUME 288ߦNUMBER 52 JOURNAL OF BIOLOGICAL CHEMISTRY 37171 at SEMMELWEIS UNIV OF MEDICINE on December , ment of the W590S-ABAC1 cells with myriocin, there was an almost complete restoration of cell surface PS (1.55-fold versus control HEK cells) (Fig. 5, A and B).
X
ABCA1 p.Trp590Ser 24220029:184:294
status: NEW188 B, primary flow cytometry data showing shift in annexin V signal in HEK293, HEK-Abca1, and HEK-W590S-Abca1 cells with or without treatment with myriocin.
X
ABCA1 p.Trp590Ser 24220029:188:95
status: NEW290 This was also indicated by our finding that myriocin increased cholesterol efflux to NaTC in HEK cells, but even more so in cells transfected with WT and particularly the W590S mutant isoform of ABCA1 (Fig. 4B).
X
ABCA1 p.Trp590Ser 24220029:290:171
status: NEW292 In fact, ABCA1 itself also raises cell surface PS, although this activity is greatly diminished in the W590S ABCA1 mutation that leads to Tangier disease (15, 24-26).
X
ABCA1 p.Trp590Ser 24220029:292:103
status: NEW293 The SM depletion-mediated increase in cell surface PS was sufficient to compensate for the defective PS translocation in the W590S-Abca1 expressing HEK cells, restoring cholesterol efflux to apoAI (Fig. 3G) and NaTC (Fig. 4B), providing direct proof that the ABCA1 PS floppase activity plays a role in ABCA1-mediated cholesterol efflux.
X
ABCA1 p.Trp590Ser 24220029:293:125
status: NEW297 This increase in cell surface PS could partially restore the activity of the PS-floppase-deficient Abca1 W590S mutation (Figs.
X
ABCA1 p.Trp590Ser 24220029:297:105
status: NEW
No.
Sentence
Comment
50
A notable exemption is the ABCA1[W590S] mutant which cross-linked stronger to apoA-I than to WT ABCA1 but had diminished capacity to promote cholesterol efflux and to promote formation of HDL (Bodzioch et al. 1999; Fitzgerald et al. 2001, 2002).
X
ABCA1 p.Trp590Ser 25522986:50:33
status: NEW
PMID: 26117661
[PubMed]
Schwendeman A et al: "The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties."
No.
Sentence
Comment
277
The comparison of in vitro cholesterol efflux by ApoA-I and ApoA-I-Milano formulated with either 1,2-dimyristoyl-rac-glycero-3-phosphocholine (DMPC) or SM was conducted in Chinese hamster ovary cells, J774 macrophages, and BHK cells transfected with ABCA1, nonfunctional ABCA1 mutant (W590S), and ABCG1 (9).
X
ABCA1 p.Trp590Ser 26117661:277:285
status: NEW
No.
Sentence
Comment
1058
The mutant W590S has a near-normal apolipoprotein binding activity but defective lipid transport (471).
X
ABCA1 p.Trp590Ser 26546829:1058:11
status: NEW